2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons by Gersh, Bernard J. et al.
§
#
C
F
A
S
S
M
t
H
H
r
p
Journal of the American College of Cardiology Vol. 58, No. 25, 2011
© 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/$36.00PRACTICE GUIDELINE
2011 ACCF/AHA Guideline for the Diagnosis and Treatment
of Hypertrophic Cardiomyopathy: Executive Summary
A Report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines
Developed in Collaboration With the American Association for Thoracic Surgery, American Society
of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America,
Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions,
and Society of Thoracic Surgeons
WRITING COMMITTEE MEMBERS*
Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair*†;
Barry J. Maron, MD, FACC, Co-Chair*†; Robert O. Bonow, MD, MACC, FAHA‡;
Joseph A. Dearani, MD, FACC§; Michael A. Fifer, MD, FACC, FAHA*†;
Mark S. Link, MD, FACC, FHRS*¶; Srihari S. Naidu, MD, FACC, FSCAI*#;
Rick A. Nishimura, MD, FACC, FAHA†; Steve R. Ommen, MD, FACC, FAHA†;
Harry Rakowski, MD, FACC, FASE†**; Christine E. Seidman, MD, FAHA†;
Jeffrey A. Towbin, MD, FACC, FAHA††; James E. Udelson, MD, FACC, FASNC‡‡§§;
Clyde W. Yancy, MD, FACC, FAHA
ACCF/AHA TASK FORCE MEMBERS
Alice K. Jacobs, MD, FACC, FAHA, Chair, 2009–2011;
Sidney C. Smith, Jr, MD, FACC, FAHA, Immediate Past Chair, 2006–2008¶¶;
Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN, FAHA;
Christopher E. Buller, MD, FACC¶¶; Mark A. Creager, MD, FACC, FAHA;
Steven M. Ettinger, MD, FACC; Robert A. Guyton, MD, FACC;
Jonathan L. Halperin, MD, FACC, FAHA; Judith S. Hochman, MD, FACC, FAHA;
Harlan M. Krumholz, MD, FACC, FAHA¶¶; Frederick G. Kushner, MD, FACC, FAHA;
Rick A. Nishimura, MD, FACC, FAHA¶¶; E. Magnus Ohman, MD, FACC;
Richard L. Page, MD, FACC, FAHA¶¶; William G. Stevenson, MD, FACC, FAHA;
Lynn G. Tarkington, RN¶¶; Clyde W. Yancy, MD, FACC, FAHA
*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other
entities may apply; see Appendix 1 for detailed information. †ACCF/AHA Representative. ‡ACCF/AHA Task Force on Performance Measures Liaison.
Society of Thoracic Surgeons Representative. American Association for Thoracic Surgery Representative. ¶Heart Rhythm Society Representative.
Society for Cardiovascular Angiography and Interventions Representative. **American Society of Echocardiography Representative. ††Pediatric
ontent Expert. ‡‡Heart Failure Society of America Representative. §§American Society of Nuclear Cardiology Representative.  ACCF/AHA Task
orce on Practice Guidelines Liaison. ¶¶Former Task Force member during this writing effort.
This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science
dvisory and Coordinating Committee in April 2011. The American Association for Thoracic Surgery, American Society of Echocardiography, American
ociety of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and
ociety of Thoracic Surgeons approved the document in June 2011.
The American College of Cardiology Foundation requests that this document be cited as follows: Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer
A, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for
he diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American
eart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58:2703–38.
This article is copublished in Circulation and the Journal of Thoracic and Cardiovascular Surgery.
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org) and the American
eart Association (my.americanheart.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail
eprints@elsevier.com.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.825ermission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at healthpermissions@elsevier.com.
P1
R
A
a
A
a
2704 Gersh et al. JACC Vol. 58, No. 25, 2011
ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summary December 13/20, 2011:2703–38TABLE OF CONTENTS
reamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2705
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2707
1.1. Methodology and Evidence Review . . . . . . .2707
1.2. Organization of the Writing Committee . . . . . .2707
1.3. Document Review and Approval . . . . . . . . . .2707
1.4. Scope of the Guideline . . . . . . . . . . . . . . . . . .2707
2. Recommendations for HCM. . . . . . . . . . . . . . . . . .2707
2.1. Genetic Testing Strategies/Family
Screening—Recommendations . . . . . . . . . . .2707
2.1.1. Genotype-Positive/Phenotype-Negative
Patients—Recommendation . . . . . . . . . . .2708
2.2. Electrocardiography—Recommendations. . . . .2708
2.3. Echocardiography—Recommendations. . . .2708
2.4. Stress Testing—Recommendations . . . . . . .2709
2.5. Cardiac Magnetic
Resonance—Recommendations . . . . . . . . . .2709
2.6. Detection of Concomitant Coronary
Disease—Recommendations . . . . . . . . . . . . .2709
2.7. Asymptomatic Patients—Recommendations. .2709
2.8. Pharmacologic
Management—Recommendations . . . . . . . .2710
2.9. Invasive Therapies—Recommendations . . . . . .2710
2.10. Pacing—Recommendations . . . . . . . . . . . . . .2711
2.11. Patients With LV Systolic
Dysfunction—Recommendations . . . . . . . . .2711
2.12. Selection of Patients for Heart
Transplantation—Recommendations . . . . . .2711
2.13. SCD Risk
Stratification—Recommendations . . . . . . . .2712
2.14. Selection of Patients for
ICDs—Recommendations . . . . . . . . . . . . . . . .2712
2.15. Selection of ICD Device
Type—Recommendations . . . . . . . . . . . . . . . .2712
2.16. Participation in Competitive or
Recreational Sports and Physical
Activity—Recommendations . . . . . . . . . . . . .2713
2.17. Management of AF—Recommendations . . . .2713
2.18. Pregnancy/Delivery—Recommendations. . . . .2714
3. Prevalence/Nomenclature/Differential
Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2714
3.1. Prevalence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2714
3.1.1. Clinical Definition and Differential
Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . .2714
3.1.2. Impact of Genetics . . . . . . . . . . . . . . . . . .2715
3.1.3. HCM Centers. . . . . . . . . . . . . . . . . . . . . .2715
4. Clinical Course and Natural History, Including
Absence of Complications . . . . . . . . . . . . . . . . . . .2716
5. Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . .2716
5.1. LVOT Obstruction . . . . . . . . . . . . . . . . . . . . . . . .2716
6. Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27176.1. Cardiovascular Magnetic Resonance . . . . .27177. Concomitant Coronary Disease . . . . . . . . . . . . . .2718
8. Choice of Imaging Modality . . . . . . . . . . . . . . . . .2718
8.1. Invasive Coronary Arteriography . . . . . . . . .2718
8.2. Noninvasive CTA . . . . . . . . . . . . . . . . . . . . . . . .2718
8.3. Single Photon Emission Computed Tomography
Myocardial Perfusion Imaging . . . . . . . . . . . . .2718
8.4. Positron Emission Tomography . . . . . . . . . . .2718
8.5. Stress Echocardiography . . . . . . . . . . . . . . . .2718
9. Management of HCM . . . . . . . . . . . . . . . . . . . . . . . .2719
9.1. Asymptomatic Patients . . . . . . . . . . . . . . . . . .2719
9.2. Symptomatic Patients . . . . . . . . . . . . . . . . . . .2720
9.3. Invasive Therapies . . . . . . . . . . . . . . . . . . . . . .2720
9.3.1. Selection of Patients . . . . . . . . . . . . . . . . .2720
9.3.2. Results of Invasive Therapy for the
Relief of LVOT Obstruction . . . . . . . . . . .2720
9.3.3. Operator Experience. . . . . . . . . . . . . . . . .2721
9.3.4. Surgical Therapy . . . . . . . . . . . . . . . . . . . .2721
9.3.4.1. OUTCOMES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2721
9.3.4.2. COMPLICATIONS . . . . . . . . . . . . . . . . . . . . . . . .2721
9.3.4.3. MITRAL VALVE ABNORMALITIES AND
OTHER ANATOMIC ISSUES . . . . . . . . . . . . . . . .2721
9.3.5. Alcohol Septal Ablation . . . . . . . . . . . . . .2722
9.3.5.1. SELECTION OF PATIENTS . . . . . . . . . . . . . . . . .2722
9.3.5.2. RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2722
9.3.5.3. COMPLICATIONS . . . . . . . . . . . . . . . . . . . . . . . .2722
9.3.6. DDD Pacing. . . . . . . . . . . . . . . . . . . . . . .2723
9.3.7. LV Systolic Dysfunction . . . . . . . . . . . . .2723
9.4. Prevention of SCD. . . . . . . . . . . . . . . . . . . . . . .2723
9.4.1. Established Risk Markers. . . . . . . . . . . . .2723
9.4.1.1. PRIOR PERSONAL HISTORY OF VENTRICULAR
FIBRILLATION, SCD, OR SUSTAINED VT . . . . .2723
9.4.1.2. FAMILY HISTORY OF SCD . . . . . . . . . . . . . . . . .2723
9.4.1.3. SYNCOPE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2723
9.4.1.4. NONSUSTAINED VENTRICULAR TACHYCARDIA. . .2723
9.4.1.5. MAXIMUM LV WALL THICKNESS . . . . . . . . . . .2723
9.4.1.6. ABNORMAL BLOOD PRESSURE RESPONSE
DURING EXERCISE. . . . . . . . . . . . . . . . . . . . . . .2724
9.4.2. Other Potential SCD Risk Modifiers. . . . .2724
9.4.2.1. LVOT OBSTRUCTION . . . . . . . . . . . . . . . . . . . . .2724
9.4.2.2. LGE ON CMR IMAGING . . . . . . . . . . . . . . . . . . .2724
9.4.2.3. LV APICAL ANEURYSM . . . . . . . . . . . . . . . . . . .2724
9.4.2.4. GENETIC MUTATIONS . . . . . . . . . . . . . . . . . . . .2724
9.4.3. Utility of SCD Risk Markers in
Clinical Practice . . . . . . . . . . . . . . . . . . . .2724
9.5. ICD Therapy in HCM . . . . . . . . . . . . . . . . . . . . .2724
9.5.1. Complications of ICD Therapy in HCM. . .2725
9.6. Participation in Competitive or
Recreational Sports and Physical Activity . . . .2725
9.7. Atrial Fibrillation . . . . . . . . . . . . . . . . . . . . . . . .2725
0. Occupational Considerations . . . . . . . . . . . . . . . .2726
eferences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2727
ppendix 1. Author Relationships With Industry
nd Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . .2736
ppendix 2. Reviewer Relationships With Industry
nd Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . .2737
PIt
cr
an
of
av
ri
ef
ab
ef
pr
pr
as
ca
an
en
ca
F
de
ca
di
ch
of
cl
se
da
fr
co
li
ag
es
P
ti
th
st
ou
in
an
ba
de
ev
w
fr
an
B
iz
pr
io
of
no
ob
w
qu
ex
C
pn
ba
L
re
F
pr
th
ci
L
il
si
to
re
is
to
co
ge
at
an
E
ti
of
th
w
ar
m
an
at
w
re
co
ap
w
of
A
on
co
te
T
m
w
de
du
m
re
C
av
A
T
by
co
ul
ic
A
re
su
2705JACC Vol. 58, No. 25, 2011 Gersh et al.
December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryreamble
is essential that the medical profession play a central role in
itically evaluating the evidence related to drugs, devices,
d procedures for the detection, management, or prevention
disease. Properly applied, rigorous, expert analysis of the
ailable data documenting absolute and relative benefits and
sks of these therapies and procedures can improve the
fectiveness of care, optimize patient outcomes, and favor-
ly affect the cost of care by focusing resources on the most
fective strategies. One important use of such data is the
oduction of clinical practice guidelines that, in turn, can
ovide a foundation for a variety of other applications such
performance measures, appropriateness use criteria, clini-
l decision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
gaged in the production of guidelines in the area of
rdiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines (Task Force) is charged with
veloping, updating, and revising practice guidelines for
rdiovascular diseases and procedures, and the Task Force
rects and oversees this effort. Writing committees are
arged with assessing the evidence as an independent group
authors to develop, update, or revise recommendations for
inical practice.
Experts in the subject under consideration have been
lected from both organizations to examine subject-specific
ta and write guidelines in partnership with representatives
om other medical practitioner and specialty groups. Writing
mmittees are specifically charged to perform a formal
terature review, weigh the strength of evidence for or
ainst particular tests, treatments, or procedures, and include
timates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of pa-
ent preference that may influence the choice of tests or
erapies are considered. When available, information from
udies on cost is considered, but data on efficacy and clinical
tcomes constitute the primary basis for recommendations
these guidelines.
In analyzing the data and developing the recommendations
d supporting text, the writing committee used evidence-
sed methodologies developed by the Task Force, which are
scribed elsewhere (1). The committee reviewed and ranked
idence supporting current recommendations with the
eight of evidence ranked as Level A if the data were derived
om multiple randomized clinical trials (RCTs) or meta-
alyses. The committee ranked available evidence as Level
when data were derived from a single RCT or nonrandom-
ed studies. Evidence was ranked as Level C when the
imary source of the recommendation was consensus opin-
n, case studies, or standard of care. In the narrative portions
these guidelines, evidence is generally presented in chro-
logical order of development. Studies are identified as
servational, retrospective, prospective, or randomized
hen appropriate. For certain conditions for which inade-
ate data are available, recommendations are based on
pert consensus and clinical experience and ranked as Level. An example is the use of penicillin for pneumococcal reeumonia, for which there are no RCTs and treatment is
sed on clinical experience. When recommendations at
evel C are supported by historical clinical data, appropriate
ferences (including clinical reviews) are cited if available.
or issues where sparse data are available, a survey of current
actice among the clinicians on the writing committee was
e basis for Level C recommendations and no references are
ted. The schema for Classification of Recommendations and
evel of Evidence is summarized in Table 1, which also
lustrates how the grading system provides an estimate of the
ze and the certainty of the treatment effect. A new addition
the ACCF/AHA methodology is separation of the Class III
commendations to delineate whether the recommendation
determined to be of “no benefit” or associated with “harm”
the patient. In addition, in view of the increasing number of
mparative effectiveness studies, comparator verbs and sug-
sted phrases for writing recommendations for the compar-
ive effectiveness of one treatment/strategy with respect to
other for Class of Recommendation I and IIa, Level of
vidence A or B only have been added.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e writing committee. Specifically, all members of the
riting committee, as well as peer reviewers of the document,
e required to disclose all relevant relationships and those 12
onths prior to initiation of the writing effort. The policies
d procedures for RWI for this guideline were those in effect
the initial meeting of this committee (March 28, 2009),
hich included 50% of the writing committee with no
levant RWI. All guideline recommendations require a
nfidential vote by the writing committee and must be
proved by a consensus of the members voting. Members
ho were recused from voting are indicated on the title page
this document with detailed information included in
ppendix 1. Members must recuse themselves from voting
any recommendations where their RWI apply. If a writing
mmittee member develops a new RWI during his/her
nure, he/she is required to notify guideline staff in writing.
hese statements are reviewed by the Task Force and all
embers during each conference call and/or meeting of the
riting committee and are updated as changes occur. For
tailed information regarding guideline policies and proce-
res, please refer to the ACCF/AHA methodology and policies
anual (1). RWI pertinent to this guideline for authors and peer
viewers are disclosed in Appendixes 1 and 2, respectively.
omprehensive disclosure information for the Task Force is also
ailable online at http://www.cardiosource.org/ACC/About-
CC/Leadership/Guidelines-and-Documents-Task-Forces.aspx.
he work of the writing committee was supported exclusively
the ACCF and AHA without commercial support. Writing
mmittee members volunteered their time for this effort.
The ACCF/AHA practice guidelines address patient pop-
ations (and healthcare providers) residing in North Amer-
a. As such, drugs that are currently unavailable in North
merica are discussed in the text without a specific class of
commendation. For studies performed in large numbers of
bjects outside of North America, each writing group
views the potential impact of different practice patterns and
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nce to the ACCF/AHA target population to determine whether
e findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
agnosis, management, and prevention of specific diseases
conditions. These practice guidelines represent a consensus
expert opinion after a thorough review of the available
rrent scientific evidence and are intended to improve
tient care. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
ble 1. Applying Classification of Recommendation and Level o
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.made by the healthcare provider and patient in light of all ade circumstances presented by that patient. Thus, there are
tuations in which deviations from these guidelines may be
propriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care. The Task Force recognizes that
tuations arise for which additional data are needed to better
form patient care; these areas will be identified within each
spective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
nce
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involvef Evide
mmend
ble, the
in diffe
dence Aversely affect outcomes, physicians and other healthcare
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December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryoviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles.
The guideline will be reviewed annually by the Task Force
d considered current unless it is updated, revised, or with-
awn from distribution. The full-text version (1a) of the
ideline is e-published in the Journal of the American College
Cardiology and Circulation and is posted on the ACC
ww.cardiosource.org) and AHA (my.americanheart.org)
orld Wide Web sites. Guidelines are official policy of both
e ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, whenever
ssible, evidence based. An extensive evidence review was
nducted through January 2011. Searches were limited to
udies, reviews, and other evidence conducted in human
bjects and published in English. Key search words in-
uded, but were not limited to, hypertrophic cardiomyopathy
CM), surgical myectomy, ablation, exercise, sudden car-
ac death (SCD), athletes, dual-chamber pacing, left ven-
icular outflow tract (LVOT) obstruction, alcohol septal
lation, automobile driving and implantable cardioverter-
fibrillators (ICDs), catheter ablation, defibrillators, genet-
s, genotype, medical management, magnetic resonance
aging, pacing, permanent pacing, phenotype, pregnancy,
sk stratification, sudden death in athletes, surgical septal
yectomy, and septal reduction. References selected and
blished in this document are representative and not all-
clusive.
.2. Organization of the Writing Committee
he committee was composed of physicians and cardiac
rgeons with expertise in HCM, invasive cardiology, non-
vasive testing and imaging, pediatric cardiology, electro-
ysiology, and genetics. The committee included represen-
tives from the American Association for Thoracic Surgery,
merican Society of Echocardiography, American Society of
uclear Cardiology, Heart Failure Society of America, Heart
hythm Society, Society for Cardiovascular Angiography
d Interventions, and the Society of Thoracic Surgeons.
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers nomi-
ted by both the ACCF and AHA, as well as 2 reviewers
ch from the American Association for Thoracic Surgery,
merican Society of Echocardiography, American Society of
uclear Cardiology, Heart Failure Society of America, Heart
hythm Society, Society for Cardiovascular Angiography
d Interventions, and the Society of Thoracic Surgeons.
ther content reviewers included members from the ACCF
dult Congenital and Pediatric Cardiology Council, ACCFurgeons’ Scientific Council, and ACCF Interventional Sci-
tific Council. All information on reviewers’ RWI was
stributed to the writing committee and is published in this
cument (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and endorsed by the
merican Association for Thoracic Surgery, American Soci-
y of Echocardiography, American Society of Nuclear Car-
ology, Heart Failure Society of America, Heart Rhythm
ociety, Society for Cardiovascular Angiography and Inter-
ntions, and Society of Thoracic Surgeons.
.4. Scope of the Guideline
lthough there are reports of this disease dating back to the
00s, the first modern pathologic description was provided
er 50 years ago by Teare (2) and the most important early
inical report by Braunwald et al. in 1964 (3).
The impetus for the guidelines is based on an appreciation
the frequency of this clinical entity and a realization that
any aspects of clinical management, including the use of
agnostic modalities and genetic testing, lack consensus.
oreover, the emergence of 2 different approaches to septal
duction therapy (septal myectomy and alcohol septal abla-
on) in addition to the ICD has created considerable contro-
rsy. The discussion and recommendations about the various
agnostic modalities apply to patients with established HCM
d to a variable extent to patients with a high index of
spicion of the disease.
Although the Task Force was aware of the lack of high
vels of evidence regarding HCM provided by clinical trials,
was believed that a guideline document based on expert
nsensus that outlines the most important diagnostic and
anagement strategies would be helpful.
To facilitate ease of use, it was decided that recommenda-
ons in the pediatric and adolescent age groups would not
pear as a separate section but instead would be integrated
to the overall content of the guideline where relevant.
. Recommendations for HCM
.1. Genetic Testing Strategies/
amily Screening—Recommendations
ASS I
Evaluation of familial inheritance and genetic counseling is
recommended as part of the assessment of patients with HCM
(4–9). (Level of Evidence: B)
Patients who undergo genetic testing should also undergo
counseling by someone knowledgeable in the genetics of
cardiovascular disease so that results and their clinical signif-
icance can be appropriately reviewed with the patient (10–14).
(Level of Evidence: B)
Screening (clinical, with or without genetic testing) is recom-
mended in first-degree relatives of patients with HCM (4–7,9,
15,16). (Level of Evidence: B)
Genetic testing for HCM and other genetic causes of unex-
plained cardiac hypertrophy is recommended in patients with
an atypical clinical presentation of HCM or when another
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of Evidence: B)
ASS IIa
Genetic testing is reasonable in the index patient to facilitate
the identification of first-degree family members at risk for
developing HCM (5,8,15). (Level of Evidence: B)
ASS IIb
The usefulness of genetic testing in the assessment of risk of
SCD in HCM is uncertain (20,21). (Level of Evidence: B)
ASS III: NO BENEFIT
Genetic testing is not indicated in relatives when the index
patient does not have a definitive pathogenic mutation (4–9,
22). (Level of Evidence: B)
Ongoing clinical screening is not indicated in genotype-
negative relatives in families with HCM (22–25). (Level of
Evidence: B)
e Data Supplement 1 for additional data regarding genetic
sting strategies/family screening.
.1.1. Genotype-Positive/Phenotype-Negative Patients—
ecommendation
ASS I
In individuals with pathogenic mutations who do not express the
HCM phenotype, it is recommended to perform serial electrocar-
diogram (ECG), transthoracic echocardiogram (TTE), and clinical
assessment at periodic intervals (12 to 18 months in children and
adolescents and about every 5 years in adults), based on the
patient’s age and change in clinical status (26–29). (Level of
Evidence: B)
.2. Electrocardiography—Recommendations
ASS I
A 12-lead ECG is recommended in the initial evaluation of
patients with HCM. (Level of Evidence: C)
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring is recommended in the initial evaluation of patients
with HCM to detect ventricular tachycardia (VT) and identify
patients who may be candidates for ICD therapy (30–33).
(Level of Evidence: B)
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring or event recording is recommended in patients with
HCM who develop palpitations or lightheadedness (30–32).
(Level of Evidence: B)
A repeat ECG is recommended for patients with HCM when
there is worsening of symptoms. (Level of Evidence: C)
A 12-lead ECG is recommended every 12 to 18 months as a
component of the screening algorithm for adolescent first-
degree relatives of patients with HCM who have no evidence of
hypertrophy on echocardiography. (Level of Evidence: C)
A 12-lead ECG is recommended as a component of the screen-
ing algorithm for first-degree relatives of patients with HCM.
(Level of Evidence: C)
ASS IIa
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring, repeated every 1 to 2 years, is reasonable inpatients with HCM who have no previous evidence of VT to
identify patients who may be candidates for ICD therapy (33).
(Level of Evidence: C)
Annual 12-lead ECGs are reasonable in patients with known
HCM who are clinically stable to evaluate for asymptomatic
changes in conduction or rhythm (i.e., atrial fibrillation [AF]).
(Level of Evidence: C)
ASS IIb
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring might be considered in adults with HCM to assess
for asymptomatic paroxysmal AF/atrial flutter. (Level of Evi-
dence: C)
.3. Echocardiography—Recommendations
ASS I
A TTE is recommended in the initial evaluation of all patients
with suspected HCM (34–41). (Level of Evidence: B)
A TTE is recommended as a component of the screening
algorithm for family members of patients with HCM unless the
family member is genotype negative in a family with known
definitive mutations (42–45). (Level of Evidence: B)
Periodic (12 to 18 months) TTE screening is recommended for
children of patients with HCM, starting by age 12 years or
earlier if a growth spurt or signs of puberty are evident and/or
when there are plans for engaging in intense competitive
sports or there is a family history of SCD (45,46). (Level of
Evidence: C)
Repeat TTE is recommended for the evaluation of patients with
HCM with a change in clinical status or new cardiovascular
event (47–53). (Level of Evidence: B)
A transesophageal echocardiogram (TEE) is recommended for
the intraoperative guidance of surgical myectomy (54–56).
(Level of Evidence: B)
TTE or TEE with intracoronary contrast injection of the candi-
date’s septal perforator(s) is recommended for the intraproce-
dural guidance of alcohol septal ablation (57–60). (Level of
Evidence: B)
TTE should be used to evaluate the effects of surgical myec-
tomy or alcohol septal ablation for obstructive HCM (60–66).
(Level of Evidence: C)
ASS IIa
TTE studies performed every 1 to 2 years can be useful in the
serial evaluation of symptomatically stable patients with HCM
to assess the degree of myocardial hypertrophy, dynamic
obstruction, and myocardial function (35,37,41). (Level of
Evidence: C)
Exercise TTE can be useful in the detection and quantification
of dynamic LVOT obstruction in the absence of resting outflow
tract obstruction in patients with HCM (48,51,53,67,68).
(Level of Evidence: B)
TEE can be useful if TTE is inconclusive for clinical decision
making about medical therapy and in situations such as
planning for myectomy, exclusion of subaortic membrane or
mitral regurgitation secondary to structural abnormalities of
the mitral valve apparatus, or in assessment for the feasibility
of alcohol septal ablation (54–56). (Level of Evidence: C)
TTE combined with the injection of an intravenous contrast
agent is reasonable if the diagnosis of apical HCM or apical
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when other imaging modalities such as cardiovascular mag-
netic resonance (CMR) are not readily available, not diagnos-
tic, or are contraindicated. (Level of Evidence: C)
Serial TTE studies are reasonable for clinically unaffected
patients who have a first-degree relative with HCM when
genetic status is unknown. Such follow-up may be considered
every 12 to 18 months for children or adolescents from
high-risk families and every 5 years for adult family members
(43–46). (Level of Evidence: C)
ASS III: NO BENEFIT
TTE studies should not be performed more frequently than
every 12 months in patients with HCM when it is unlikely that
any changes have occurred that would have an impact on
clinical decision making. (Level of Evidence: C)
Routine TEE and/or contrast echocardiography is not recom-
mended when TTE images are diagnostic of HCM and/or there
is no suspicion of fixed obstruction or intrinsic mitral valve
pathology. (Level of Evidence: C)
.4. Stress Testing—Recommendations
ASS IIa
Treadmill exercise testing is reasonable to determine func-
tional capacity and response to therapy in patients with HCM.
(Level of Evidence: C)
Treadmill testing with monitoring of an ECG and blood pressure
is reasonable for SCD risk stratification in patients with HCM
(69–71). (Level of Evidence: B)
In patients with HCM who do not have a resting peak instan-
taneous gradient of greater than or equal to 50 mm Hg,
exercise echocardiography is reasonable for the detection and
quantification of exercise-induced dynamic LVOT obstruction
(67,70–72). (Level of Evidence: B)
.5. Cardiac Magnetic Resonance—
ecommendations
ASS I
CMR imaging is indicated in patients with suspected HCM
when echocardiography is inconclusive for diagnosis (73,74).
(Level of Evidence: B)
CMR imaging is indicated in patients with known HCM when
additional information that may have an impact on manage-
ment or decision making regarding invasive management, such
as magnitude and distribution of hypertrophy or anatomy of the
mitral valve apparatus or papillary muscles, is not adequately
defined with echocardiography (73–77). (Level of Evidence: B)
ASS IIa
CMR imaging is reasonable in patients with HCM to define
apical hypertrophy and/or aneurysm if echocardiography is
inconclusive (73,75). (Level of Evidence: B)
ASS IIb
In selected patients with known HCM, when SCD risk stratifi-
cation is inconclusive after documentation of the conventional
risk factors (Section 2.13), CMR imaging with assessment of
late gadolinium enhancement (LGE) may be considered in resolv-
ing clinical decision making (78–82). (Level of Evidence: C)CMR imaging may be considered in patients with LV hypertro-
phy and the suspicion of alternative diagnoses to HCM, includ-
ing cardiac amyloidosis, Fabry disease, and genetic phenocop-
ies such as LAMP2 cardiomyopathy (83–85). (Level of
Evidence: C)
.6. Detection of Concomitant Coronary
isease—Recommendations
ASS I
Coronary arteriography (invasive or computed tomographic imag-
ing) is indicated in patients with HCM with chest discomfort who
have an intermediate to high likelihood of coronary artery disease
(CAD) when the identification of concomitant CAD will change
management strategies. (Level of Evidence: C)
ASS IIa
Assessment of coronary anatomy with computed tomographic
angiography (CTA) is reasonable for patients with HCM with
chest discomfort and a low likelihood of CAD to assess for
possible concomitant CAD. (Level of Evidence: C)
Assessment of ischemia or perfusion abnormalities suggestive
of CAD with single photon emission computed tomography
(SPECT) or positron emission tomography (PET) myocardial
perfusion imaging (MPI; because of excellent negative predic-
tive value) is reasonable in patients with HCM with chest
discomfort and a low likelihood of CAD to rule out possible
concomitant CAD. (Level of Evidence: C)
ASS III: NO BENEFIT
Routine SPECT MPI or stress echocardiography is not indi-
cated for detection of “silent” CAD-related ischemia in patients
with HCM who are asymptomatic. (Level of Evidence: C)
Assessment for the presence of blunted flow reserve (micro-
vascular ischemia) using quantitative myocardial blood flow
measurements by PET is not indicated for the assessment of
prognosis in patients with HCM. (Level of Evidence: C)
.7. Asymptomatic Patients—
ecommendations
ASS I
For patients with HCM, it is recommended that comorbidities that
may contribute to cardiovascular disease (e.g., hypertension,
diabetes, hyperlipidemia, obesity) be treated in compliance with
relevant existing guidelines (86). (Level of Evidence: C)
ASS IIa
Low-intensity aerobic exercise is reasonable as part of a
healthy lifestyle for patients with HCM (32,87). (Level of
Evidence: C)
ASS IIb
The usefulness of beta blockade and calcium channel blockers
to alter clinical outcome is not well established for the man-
agement of asymptomatic patients with HCM with or without
obstruction (32). (Level of Evidence: C)
ASS III: HARM
Septal reduction therapy should not be performed for asymp-
tomatic adult and pediatric patients with HCM with normal
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(32,38). (Level of Evidence: C)
In patients with HCM with resting or provocable outflow tract
obstruction, regardless of symptom status, pure vasodilators
and high-dose diuretics are potentially harmful (3,38). (Level of
Evidence: C)
.8. Pharmacologic Management—
ecommendations
ASS I
Beta-blocking drugs are recommended for the treatment of
symptoms (angina or dyspnea) in adult patients with obstruc-
tive or nonobstructive HCM but should be used with caution in
patients with sinus bradycardia or severe conduction disease
(3,32,36,38,88–96). (Level of Evidence: B)
If low doses of beta-blocking drugs are ineffective for control-
ling symptoms (angina or dyspnea) in patients with HCM, it is
useful to titrate the dose to a resting heart rate of less than 60
to 65 bpm (up to generally accepted and recommended maxi-
mum doses of these drugs) (3,32,36,89–96). (Level of Evi-
dence: B)
Verapamil therapy (starting in low doses and titrating up to
480 mg/d) is recommended for the treatment of symptoms
(angina or dyspnea) in patients with obstructive or nonobstruc-
tive HCM who do not respond to beta-blocking drugs or who
have side effects or contraindications to beta-blocking drugs.
However, verapamil should be used with caution in patients
with high gradients, advanced heart failure, or sinus bradycar-
dia (32,36,88,97–101). (Level of Evidence: B)
Intravenous phenylephrine (or another pure vasoconstricting
agent) is recommended for the treatment of acute hypotension
in patients with obstructive HCM who do not respond to fluid
administration (36,102–104). (Level of Evidence: B)
ASS IIa
It is reasonable to combine disopyramide with a beta-blocking
drug or verapamil in the treatment of symptoms (angina or
dyspnea) in patients with obstructive HCM who do not respond
to beta-blocking drugs or verapamil alone (32,36,88,105–
108). (Level of Evidence: B)
It is reasonable to add oral diuretics in patients with nonob-
structive HCM when dyspnea persists despite the use of beta
blockers or verapamil or their combination (41,88). (Level of
Evidence: C)
ASS IIb
Beta-blocking drugs might be useful in the treatment of symp-
toms (angina or dyspnea) in children or adolescents with HCM,
but patients treated with these drugs should be monitored for
side effects, including depression, fatigue, or impaired scho-
lastic performance. (Level of Evidence: C)
It may be reasonable to add oral diuretics with caution to
patients with obstructive HCM when congestive symptoms
persist despite the use of beta blockers or verapamil or their
combination (32,36,88). (Level of Evidence: C)
The usefulness of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers in the treatment of symptoms
(angina or dyspnea) in patients with HCM with preserved
systolic function is not well established, and these drugsshould be used cautiously (if at all) in patients with resting or
provocable LVOT obstruction. (Level of Evidence: C)
In patients with HCM who do not tolerate verapamil or in whom
verapamil is contraindicated, diltiazem may be considered.
(Level of Evidence: C)
ASS III: HARM
Nifedipine or other dihydropyridine calcium channel-blocking
drugs are potentially harmful for treatment of symptoms (an-
gina or dyspnea) in patients with HCM who have resting or
provocable LVOT obstruction. (Level of Evidence: C)
Verapamil is potentially harmful in patients with obstructive
HCM in the setting of systemic hypotension or severe dyspnea
at rest. (Level of Evidence: C)
Digitalis is potentially harmful in the treatment of dyspnea in
patients with HCM and in the absence of AF (3,32,36,109–
111). (Level of Evidence: B)
The use of disopyramide alone without beta blockers or vera-
pamil is potentially harmful in the treatment of symptoms
(angina or dyspnea) in patients with HCM with AF because
disopyramide may enhance atrioventricular conduction and
increase the ventricular rate during episodes of AF (32,40,88,
112–117). (Level of Evidence: B)
Dopamine, dobutamine, norepinephrine, and other intravenous
positive inotropic drugs are potentially harmful for the treat-
ment of acute hypotension in patients with obstructive HCM
(3,102–104,118–121). (Level of Evidence: B)
.9. Invasive Therapies—Recommendations
ASS I
Septal reduction therapy should be performed only by experi-
enced operators* in the context of a comprehensive HCM
clinical program and only for the treatment of eligible patients
with severe drug-refractory symptoms and LVOT obstruction†
(122). (Level of Evidence: C)
ASS IIa
Consultation with centers experienced in performing both
surgical septal myectomy and alcohol septal ablation is rea-
sonable when discussing treatment options for eligible pa-
tients with HCM with severe drug-refractory symptoms and
LVOT obstruction. (Level of Evidence: C)
Surgical septal myectomy, when performed in experienced
centers, can be beneficial and is the first consideration for the
majority of eligible patients with HCM with severe drug-
refractory symptoms and LVOT obstruction (60,64,65,123–
125). (Level of Evidence: B)
xperienced operators are defined as an individual operator with a cumulative case
lume of at least 20 procedures or an individual operator who is working in a
dicated HCM program with a cumulative total of at least 50 procedures (Section
3.3).
†Eligible patients are defined by all of the following:
a. Clinical: Severe dyspnea or chest pain (usually New York Heart Association
[NYHA] functional classes III or IV) or occasionally other exertional
symptoms (such as syncope or near syncope) that interfere with everyday
activity or quality of life despite optimal medical therapy.
b. Hemodynamic: Dynamic LVOT gradient at rest or with physiologic provo-
cation 50 mmHg associated with septal hypertrophy and systolic anterior
motion (SAM) of the mitral valve.
c. Anatomic: Targeted anterior septal thickness sufficient to perform the proce-
dure safely and effectively in the judgment of the individual operator.
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centers, can be beneficial in symptomatic children with HCM
and severe resting obstruction (>50 mm Hg) for whom stan-
dard medical therapy has failed (126). (Level of Evidence: C)
When surgery is contraindicated or the risk is considered
unacceptable because of serious comorbidities or advanced
age, alcohol septal ablation, when performed in experienced
centers, can be beneficial in eligible adult patients with HCM
with LVOT obstruction and severe drug-refractory symptoms
(usually NYHA functional classes III or IV) (60,62,127–131).
(Level of Evidence: B)
ASS IIb
Alcohol septal ablation, when performed in experienced cen-
ters, may be considered as an alternative to surgical myectomy
for eligible adult patients with HCM with severe drug-refractory
symptoms and LVOT obstruction when, after a balanced and
thorough discussion, the patient expresses a preference for
septal ablation (62,123,128,130,131). (Level of Evidence: B)
The effectiveness of alcohol septal ablation is uncertain in
patients with HCM with marked (i.e., >30 mm) septal hyper-
trophy, and therefore the procedure is generally discouraged in
such patients. (Level of Evidence: C)
ASS III: HARM
Septal reduction therapy should not be done for adult patients
with HCM who are asymptomatic with normal exercise toler-
ance or whose symptoms are controlled or minimized on
optimal medical therapy. (Level of Evidence: C)
Septal reduction therapy should not be done unless performed
as part of a program dedicated to the longitudinal and multi-
disciplinary care of patients with HCM. (Level of Evidence: C)
Mitral valve replacement for relief of LVOT obstruction should
not be performed in patients with HCM in whom septal reduc-
tion therapy is an option. (Level of Evidence: C)
Alcohol septal ablation should not be done in patients with
HCM with concomitant disease that independently warrants
surgical correction (e.g., coronary artery bypass grafting for
CAD, mitral valve repair for ruptured chordae) in whom surgical
myectomy can be performed as part of the operation. (Level of
Evidence: C)
Alcohol septal ablation should not be done in patients with
HCM who are less than 21 years of age and is discouraged in
adults less than 40 years of age if myectomy is a viable option.
(Level of Evidence: C)
e Data Supplement 2 for additional data regarding inva-
ve therapies.
.10. Pacing—Recommendations
ASS IIa
In patients with HCM who have had a dual-chamber device
implanted for non-HCM indications, it is reasonable to consider
a trial of dual-chamber atrial-ventricular pacing (from the right
ventricular apex) for the relief of symptoms attributable to
LVOT obstruction (132–135). (Level of Evidence: B)
ASS IIb
Permanent pacing may be considered in medically refractory
symptomatic patients with obstructive HCM who are subopti- mmal candidates for septal reduction therapy (132–136). (Level
of Evidence: B)
ASS III: NO BENEFIT
Permanent pacemaker implantation for the purpose of reducing
gradient should not be performed in patients with HCM who are
asymptomatic or whose symptoms are medically controlled
(136–138). (Level of Evidence: C)
Permanent pacemaker implantation should not be performed
as a first-line therapy to relieve symptoms in medically refrac-
tory symptomatic patients with HCM and LVOT obstruction
who are candidates for septal reduction (136–138). (Level of
Evidence: B)
e Data Supplement 3 for additional data regarding pacing.
.11. Patients With LV Systolic Dysfunction—
ecommendations
ASS I
Patients with nonobstructive HCM who develop systolic dys-
function with an ejection fraction (EF) less than or equal to
50% should be treated according to evidence-based medical
therapy for adults with other forms of heart failure with reduced
EF, including angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, beta blockers, and other indicated
drugs (49,139). (Level of Evidence: B)
Other concomitant causes of systolic dysfunction (such as
CAD) should be considered as potential contributors to systolic
dysfunction in patients with HCM. (Level of Evidence: C)
ASS IIb
ICD therapy may be considered in adult patients with advanced
(as defined by NYHA functional class III or IV heart failure)
nonobstructive HCM, on maximal medical therapy, and EF less
than or equal to 50%, who do not otherwise have an indication
for an ICD (49). (Level of Evidence: C)
For patients with HCM who develop systolic dysfunction, it may
be reasonable to reassess the use of negative inotropic agents
previously indicated, for example, verapamil, diltiazem, or
disopyramide, and to consider discontinuing those therapies.
(Level of Evidence: C)
.12. Selection of Patients for Heart
ransplantation—Recommendations
ASS I
Patients with advanced heart failure (end-stage*) and nonob-
structive HCM not otherwise amenable to other treatment
interventions, with EF less than 50% (or occasionally with
preserved EF), should be considered for heart transplantation
(49,140). (Level of Evidence: B)
Symptomatic children with HCM with restrictive physiology
who are not responsive to or appropriate candidates for other
therapeutic interventions should be considered for heart trans-
plantation (141,142). (Level of Evidence: C)
haracterized by systolic dysfunction (EF 50%), often associated with LV
modeling, including cavity enlargement and wall thinning, and because of diffuse
yocardial scarring.
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Heart transplantation should not be performed in mildly symp-
tomatic patients of any age with HCM. (Level of Evidence: C)
.13. SCD Risk Stratification—
ecommendations
ASS I
All patients with HCM should undergo comprehensive SCD risk
stratification at initial evaluation to determine the presence of
the following (30,31,143–152): (Level of Evidence: B)
a. A personal history for ventricular fibrillation, sustained VT,
or SCD events, including appropriate ICD therapy for ven-
tricular tachyarrhythmias.†
b. A family history for SCD events, including appropriate ICD
therapy for ventricular tachyarrhythmias.†
c. Unexplained syncope.
d. Documented nonsustained ventricular tachycardia (NSVT)
defined as 3 or more beats at greater than or equal to 120
bpm on ambulatory (Holter) ECG.
e. Maximal LV wall thickness greater than or equal to 30 mm.
ASS IIa
It is reasonable to assess blood pressure response during
exercise as part of SCD risk stratification in patients with HCM
(30,71,149). (Level of Evidence: B)
SCD risk stratification is reasonable on a periodic basis (every
12 to 24 months) for patients with HCM who have not
undergone ICD implantation but would otherwise be eligible in
the event that risk factors are identified (12 to 24 months).
(Level of Evidence: C)
ASS IIb
The usefulness of the following potential SCD risk modifiers is
unclear but might be considered in selected patients with HCM
for whom risk remains borderline after documentation of con-
ventional risk factors:
a. CMR imaging with LGE (78,82). (Level of Evidence: C)
b. Double and compound mutations (i.e., >1). (Level of Evi-
dence: C)
c. Marked LVOT obstruction (30,48,51,149). (Level of Evi-
dence: B)
ASS III: HARM
Invasive electrophysiologic testing as routine SCD risk strati-
fication for patients with HCM should not be performed. (Level
of Evidence: C)
e Data Supplement 4 for additional data regarding SCD
sk stratification.
.14. Selection of Patients for ICDs—
ecommendations
ASS I
The decision to place an ICD in patients with HCM should
include application of individual clinical judgment, as well as a
ppropriate ICD discharge is defined as ICD therapy triggered by VT or
ntricular fibrillation, documented by stored intracardiac electrogram or cycle-
gth data, in conjunction with the patient’s symptoms immediately before andter device discharge. ‡Sthorough discussion of the strength of evidence, benefits, and
risks to allow the informed patient’s active participation in
decision making (Figure 1) (144,150,153,154). (Level of Evi-
dence: C)
ICD placement is recommended for patients with HCM with
prior documented cardiac arrest, ventricular fibrillation, or
hemodynamically significant VT (145,146,148,150). (Level of
Evidence: B)
ASS IIa
It is reasonable to recommend an ICD for patients with HCM
with:
a. Sudden death presumably caused by HCM in 1 or more
first-degree relatives (155). (Level of Evidence: C)
b. A maximum LV wall thickness greater than or equal to 30
mm (147,156–158). (Level of Evidence: C)
c. One or more recent, unexplained syncopal episodes (152).
(Level of Evidence: C)
An ICD can be useful in select patients with NSVT (particularly
those <30 years of age) in the presence of other SCD risk
factors or modifiers‡ (33,144). (Level of Evidence: C)
An ICD can be useful in select patients with HCM with an
abnormal blood pressure response with exercise in the pres-
ence of other SCD risk factors or modifiers‡ (70,71,149).
(Level of Evidence: C)
It is reasonable to recommend an ICD for high-risk children with
HCM, based on unexplained syncope, massive LV hypertrophy,
or family history of SCD, after taking into account the relatively
high complication rate of long-term ICD implantation. (Level of
Evidence: C)
ASS IIb
The usefulness of an ICD is uncertain in patients with HCM with
isolated bursts of NSVT when in the absence of any other SCD
risk factors or modifiers‡ (144). (Level of Evidence: C)
The usefulness of an ICD is uncertain in patients with HCM with
an abnormal blood pressure response with exercise when in the
absence of any other SCD risk factors or modifiers,‡ particu-
larly in the presence of significant outflow obstruction
(70,71,149). (Level of Evidence: C)
ASS III: HARM
ICD placement as a routine strategy in patients with HCM
without an indication of increased risk is potentially harmful.
(Level of Evidence: C)
ICD placement as a strategy to permit patients with HCM to
participate in competitive athletics is potentially harmful.
(Level of Evidence: C)
ICD placement in patients who have an identified HCM geno-
type in the absence of clinical manifestations of HCM is
potentially harmful. (Level of Evidence: C)
.15. Selection of ICD Device Type—
ecommendations
ASS IIa
In patients with HCM who meet indications for ICD implanta-
tion, single-chamber devices are reasonable in younger pa-CD risk modifiers are discussed in Section 9.4.2.
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(Level of Evidence: B)
In patients with HCM who meet indications for ICD implanta-
tion, dual-chamber ICDs are reasonable for patients with sinus
bradycardia and/or paroxysmal AF (159). (Level of Evidence: C)
In patients with HCM who meet indications for ICD implanta-
tion, dual-chamber ICDs are reasonable for patients with ele-
vated resting outflow gradients greater than 50 mm Hg and
significant heart failure symptoms who may benefit from right
ventricular pacing (most commonly, but not limited to, patients
>65 years of age) (136–138,159). (Level of Evidence: B)
.16. Participation in Competitive or
ecreational Sports and Physical Activity—
ecommendations
ASS IIa
It is reasonable for patients with HCM to participate in
low-intensity competitive sports (e.g., golf and bowling)
(163,164). (Level of Evidence: C)
It is reasonable for patients with HCM to participate in a range
of recreational sporting activities as outlined in Table 2 (87).
(Level of Evidence: C)
ASS III: HARM
Patients with HCM should not participate in intense competi-
tive sports regardless of age, sex, race, presence or absence of cleLVOT obstruction, prior septal reduction therapy, or implanta-
tion of a cardioverter-defibrillator for high-risk status (163–169).
(Level of Evidence: C)
.17. Management of AF—Recommendations
ASS I
Anticoagulation with vitamin K antagonists (i.e., warfarin, to
an international normalized ratio of 2.0 to 3.0) is indicated in
patients with paroxysmal, persistent, or chronic AF and HCM
(170–172). (Anticoagulation with direct thrombin inhibitors
[i.e., dabigatran§] may represent another option to reduce the
risk of thromboembolic events, but data for patients with HCM
are not available (173).) (Level of Evidence: C)
Ventricular rate control in patients with HCM with AF is
indicated for rapid ventricular rates and can require high doses
of beta antagonists and nondihydropyridine calcium channel
blockers (170,172). (Level of Evidence: C)
ASS IIa
Disopyramide (with ventricular rate-controlling agents) and
amiodarone are reasonable antiarrhythmic agents for AF in
patients with HCM (170,174). (Level of Evidence: B)
abigatran should not be used in patients with prosthetic valves, hemodynamically
nificant valve disease, advanced liver failure, or severe renal failure (creatinine
Figure 1. Indications for ICDs in HCM. SCD
risk modifiers include established risk factors
and emerging risk modifiers (Section 9.4.2).
BP indicates blood pressure; ICD, implantable
cardioverter-defibrillator; LV, left ventricular;
SCD, sudden cardiac death; SD, sudden
death; and VT, ventricular tachycardia.arance 15 mL/min) (173).
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ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summary December 13/20, 2011:2703–38Radiofrequency ablation for AF can be beneficial in patients
with HCM who have refractory symptoms or who are unable to
take antiarrhythmic drugs (175–179). (Level of Evidence: B)
Maze procedure with closure of left atrial appendage is reason-
able in patients with HCM with a history of AF, either during
septal myectomy or as an isolated procedure in selected
patients. (Level of Evidence: C)
ASS IIb
Sotalol, dofetilide, and dronedarone might be considered alter-
native antiarrhythmic agents in patients with HCM, especially
in those with an ICD, but clinical experience is limited. (Level
of Evidence: C)
.18. Pregnancy/Delivery—Recommendations
ASS I
In women with HCM who are asymptomatic or whose symp-
toms are controlled with beta-blocking drugs, the drugs should
be continued during pregnancy, but increased surveillance for
fetal bradycardia or other complications is warranted (43,44,
180,181). (Level of Evidence: C)
For patients (mother or father) with HCM, genetic counseling
is indicated before planned conception. (Level of Evidence: C)
In women with HCM and resting or provocable LVOT obstruc-
tion greater than or equal to 50 mm Hg and/or cardiac
symptoms not controlled by medical therapy alone, pregnancy
is associated with increased risk, and these patients should be
referred to a high-risk obstetrician. (Level of Evidence: C)
The diagnosis of HCM among asymptomatic women is not
considered a contraindication for pregnancy, but patients
should be carefully evaluated in regard to the risk of pregnancy.
(Level of Evidence: C)
ASS IIa
For women with HCM whose symptoms are controlled (mild to
moderate), pregnancy is reasonable, but expert maternal/fetal
medical specialist care, including cardiovascular and prenatal
monitoring, is advised. (Level of Evidence: C)
ASS III: HARM
For women with advanced heart failure symptoms and HCM,
pregnancy is associated with excess morbidity/mortality.
(Level of Evidence: C)
. Prevalence/Nomenclature/Differential
iagnosis
.1. Prevalence
CM is a common genetic cardiovascular disease. In addi-
on, HCM is a global disease (182), with epidemiological
udies from several parts of the world (183) reporting a
milar prevalence of LV hypertrophy, the quintessential
enotype of HCM, to be about 0.2% (i.e., 1:500) in the
neral population, which is equivalent to at least 600,000
ople affected in the United States (184).
.1.1. Clinical Definition and Differential Diagnosis
CM is the preferred nomenclature to describe this diseaseble 2. Recommendations for the Acceptability of
ecreational (Noncompetitive) Sports Activities and Exercise in
tients With HCM*
tensity Level Eligibility Scale for HCM†
gh
Basketball (full court) 0
Basketball (half court) 0
Body building‡ 1
Gymnastics 2
Ice hockey‡ 0
Racquetball/squash 0
Rock climbing‡ 1
Running (sprinting) 0
Skiing (downhill)‡ 2
Skiing (cross-country) 2
Soccer 0
Tennis (singles) 0
Touch (flag) football 1
Windsurfing§ 1
oderate
Baseball/softball 2
Biking 4
Hiking 3
Modest hiking 4
Motorcycling‡ 3
Jogging 3
Sailing§ 3
Surfing§ 2
Swimming (laps)§ 5
Tennis (doubles) 4
Treadmill/stationary bicycle 5
Weightlifting (free weights)‡ 1
w
Bowling 5
Brisk walking 5
Golf 5
Horseback riding‡ 3
Scuba diving§ 0
Skating¶ 5
Snorkeling§ 5
Weights (nonfree weights) 4
*Recreational sports are categorized according to high, moderate, and low
vels of exercise and graded on a relative scale (from 0 to 5) for eligibility, with
to 1 indicating generally not advised or strongly discouraged; 4 to 5, probably
rmitted; and 2 to 3, intermediate and to be assessed clinically on an
dividual basis. The designations of high, moderate, and low levels of exercise
e equivalent to an estimated 6, 4 to 6, and 4 metabolic equivalents,
spectively.
†Assumes absence of laboratory DNA genotyping data; therefore, limited to
inical diagnosis.
‡These sports involve the potential for traumatic injury, which should be
ken into consideration for individuals with a risk for impaired consciousness.
§The possibility of impaired consciousness occurring during water-related
tivities should be taken into account with respect to the individual patient’s
inical profile.
Recommendations generally differ from those for weight-training machines
onfree weights), based largely on the potential risks of traumatic injury
sociated with episodes of impaired consciousness during bench-press
aneuvers; otherwise, the physiologic effects of all weight-training activities
e regarded as similar with respect to the present recommendations.
¶Individual sporting activity not associated with the team sport of ice
ckey.85), although confusion over the names used to characterize
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December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryis entity has arisen over the years in part because one third
patients have no obstruction either at rest or with physio-
gic provocation (67). The generally accepted definition of
CM is a disease state characterized by unexplained LV
pertrophy associated with nondilated ventricular chambers
the absence of another cardiac or systemic disease that
self would be capable of producing the magnitude of
pertrophy evident in a given patient (32,38,184–187), with
e caveat that patients who are genotype positive may be
enotypically negative without overt hypertrophy (188,189).
linically, HCM is usually recognized by a maximal LV wall
ickness15 mm. In the case of children, increased LV wall
ickness is defined as wall thickness 2 standard deviations
ove the mean (z score 2) for age, sex, or body size.
owever, it should be underscored that in principle, any
gree of wall thickness is compatible with the presence of
e HCM genetic substrate. Furthermore, although a myriad
patterns and distribution of LV hypertrophy (including
ffuse and marked) have been reported in HCM (37,76,190),
out one third of patients have largely segmental wall
ickening involving only a small portion of the left ventricle,
d indeed, such patients with HCM usually have normal
lculated LV mass (76).
Differential diagnosis of HCM and other cardiac conditions
ith LV hypertrophy) may arise, most commonly with
pertensive heart disease and the physiologic remodeling
sociated with athletic training (“athlete’s heart”) (191–195),
ually when maximum wall thickness is in the modest range
13 to 15 mm.
These important distinctions are often resolved by nonin-
sive markers, including sarcomeric mutations or family
story of HCM, LV cavity dimension, diastolic function,
ttern of LV hypertrophy, or short deconditioning periods
91–195).
It is evident that metabolic or infiltrative storage disorders
ith LV hypertrophy in babies, older children, and young
ults can mimic clinically diagnosed HCM (attributable to
rcomeric protein mutations), for example, conditions such
mitochondrial disease (196,197), Fabry disease (198), ororage diseases caused by mutations in the genes encoding
e -2-regulatory subunit of the adenosine monophosphate
MP)-activated protein kinase (PRKAG2) or the X-linked
sosome-associated membrane protein gene (LAMP2;
anon disease) (4,199–201). Use of the term HCM is not
propriate to describe these and other patients with LV
pertrophy that occurs in the context of a multisystem
sorder (202–206) (Figure 2). In addition, differential diag-
sis of HCM may require distinction from dilated cardio-
yopathy when HCM presents in the end stage (49).
.1.2. Impact of Genetics
n the basis of the genotype-phenotype data available at this
me, HCM is regarded here as a disease entity caused by
tosomal dominant mutations in genes encoding protein
mponents of the sarcomere and its constituent myofilament
ements (43,199,207,208). Intergenetic diversity is com-
unded by considerable intragene heterogeneity, with
1,400 mutations identified among at least 8 genes. The
rrent weight of evidence supports the view that the vast
ajority of genes and mutations responsible for clinically
agnosed HCM encode proteins within and associated with
e sarcomere, accounting in large measure for those patients
scribed in the voluminous amount of HCM literature
blished over 50 years (43,199,207,208).
.1.3. HCM Centers
he writing committee considers it important to emphasize
at HCM is a complex disease entity with a broad (and
creasing) clinical and genetic spectrum (38). Although
CM is one of the most common forms of genetic heart
sease and relatively common in the general population
84), this disease entity is infrequent in general clinical
actice, with most cardiologists responsible for the care of
ly a few patients with HCM (209). This principle has led to
impetus for establishing clinical programs of excellence—
ually within established centers—in which cardiovascular
re is focused on the management of HCM (i.e., “HCM
nters”) (209,210).
Figure 2. Summary of the nomenclature that
distinguishes HCM from other genetic dis-
eases associated with LV hypertrophy. At
this time the overwhelming evidence links the
clinical diagnosis of HCM with a variety of
genes encoding protein components of the
cardiac sarcomere. However, it is possible
that in the future other nonsarcomeric (but
also nonmetabolic) genes may prove to cause
HCM. †An example is Noonan syndrome with
cardiomyopathy. Modified with permission
from Maron et al. (187).
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ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summary December 13/20, 2011:2703–38. Clinical Course and Natural History,
cluding Absence of Complications
CM is a heterogeneous cardiac disease with a diverse
inical presentation and course, presenting in all age groups
om infancy to the very elderly (32,38,49,51). Most affected
dividuals probably achieve a normal life expectancy with-
t disability or the necessity for major therapeutic interven-
ons (211–214). On the other hand, in some patients, HCM is
sociated with disease complications that may be profound,
ith the potential to result in disease progression or prema-
re death (32,38,49,51,147,156). When the disease does
sult in significant complications, there are 3 relatively
screte but not mutually exclusive pathways of clinical
ogression (Figure 3):
SCD due to unpredictable ventricular tachyarrhythmias,
most commonly in asymptomatic patients 35 years of
age (50,144,147,150,153,154,156,166,168,215) (including
competitive athletes) (166,168).
Heart failure characterized by exertional dyspnea (with or
without chest pain) that may be progressive (49).
AF, also associated with various degrees of heart failure
(172) and an increased risk of systemic thromboembolism
and stroke.
The natural history of HCM can be altered by a number of
erapeutic interventions: ICDs for secondary or primary
evention of sudden death in patients with risk factors
50,153,154); drugs appropriate to control heart failure
mptoms (principally those of exertional dyspnea and chest
scomfort) (32,38), surgical septal myectomy (64) or alcohol
ptal ablation (60) for progressive and drug-refractory heart
ilure caused by LVOT obstruction; heart transplantation for
stolic (or less frequently, intractable diastolic) dysfunction
sociated with severe unrelenting symptoms (49); and drug
erapy or possibly radiofrequency ablation or surgical maze
ocedure for AF (175,178,179).
. Pathophysiology
he pathophysiology of HCM is complex and consists of
ultiple interrelated abnormalities, including LVOT obstruc-
gure 3. Prognosis profiles for HCM and targets for therapy.
F indicates atrial fibrillation. Modified with permission from Ma-
n et al. (32).on, diastolic dysfunction, mitral regurgitation, myocardial thchemia, and arrhythmias (38,40,41). It is clinically impor-
nt to distinguish between the obstructive and nonobstructive
rms of HCM because management strategies are largely
pendent on the presence or absence of symptoms caused by
struction.
.1. LVOT Obstruction
he original observations by Brock (216) and Braunwald et
. (3) emphasized the functional subvalvular LVOT gradient,
hich was highly influenced by alterations in the load and
ntractility of the left ventricle. The clinical significance of
e outflow tract gradient has periodically been controversial
17–220), but careful studies have shown definitively that
ue mechanical obstruction to outflow does occur (40,41).
or HCM, it is the peak instantaneous LV outflow gradient
ther than the mean gradient that influences treatment
cisions (Table 3).
Outflow obstruction usually occurs in HCM by virtue of
itral valve SAM and mitral-septal contact. Muscular ob-
ruction can also be present in the midcavitary region,
casionally because of hypertrophied papillary muscles
utting the septum (223) or anomalous papillary muscle
sertion into the anterior mitral leaflet (224).
Obstruction to LV outflow is dynamic, varying with
ading conditions and contractility of the ventricle (3).
creased myocardial contractility, decreased ventricular vol-
e, or decreased afterload increases the degree of subaortic
struction. Patients may have little or no obstruction of the
VOT at rest but can generate large LVOT gradients under
nditions such as exercise, the strain phase of the Valsalva
aneuver, or during pharmacologic provocation (40,41).
here is often large spontaneous variation in the severity of
e gradient during day-to-day activities or even with food or
cohol intake (225); exacerbation of symptoms during the
stprandial period is common. Importantly, it has been well
tablished that LVOT obstruction contributes to the debili-
ting heart failure–related symptoms that may occur in HCM
0,41), and is also a major determinant of outcome (51).
The presence and magnitude of outflow obstruction are
ually assessed with 2-dimensional echocardiography and
ntinuous wave Doppler. Combining exercise testing with
oppler echocardiography is useful in identifying the pres-
ce of physiologically provocable LVOT obstruction and is
rticularly helpful in patients with symptoms during routine
ble 3. Definitions of Dynamic Left Ventricular Outflow Tract
bstruction
modynamic State Conditions Outflow Gradient*
sal obstruction Rest 30 mm Hg†
nobstructive Rest 30 mm Hg
Physiologically provoked 30 mm Hg
bile obstruction Rest 30 mm Hg†
Physiologically provoked 30 mm Hg†
*Either the peak instantaneous continuous wave Doppler gradient or the
ak-to-peak cardiac catheterization gradient, which are equivalent in hyper-
phic cardiomyopathy (221,222).
†Gradients50 mm Hg either at rest or with provocation are considered the
reshold for septal reduction therapy in severely symptomatic patients.
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December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryysical activities who do not manifest outflow obstruction at
st (67). Provocation with dobutamine infusion during
oppler echocardiography is no longer recommended as a
rategy to induce outflow gradients in HCM.
. Diagnosis
he clinical diagnosis of HCM is conventionally made with
rdiac imaging, at present most commonly with 2-dimensional
hocardiography and increasingly with CMR. Morphologic
agnosis is based on the presence of a hypertrophied and
ndilated left ventricle in the absence of another cardiac or
stemic disease capable of producing the magnitude of
pertrophy evident in a patient (usually 15 mm in an adult
the equivalent relative to body surface area in children).
enetic testing, which is now commercially available, is a
werful strategy for definitive diagnosis of affected genetic
atus and is currently used most effectively in the identifi-
tion of affected relatives in families known to have HCM.
HCM is caused by an autosomal dominant mutation in
nes that encode sarcomere proteins or sarcomere-
sociated proteins. The most vigorous evidence indicates
at 8 genes are known to definitively cause HCM: beta
yosin heavy chain, myosin binding protein C, troponin T,
oponin I, alpha tropomyosin, actin, regulatory light chain,
d essential light chain (43,186,187,199,207,208). In addi-
on, actinin and myozenin are associated with less definitive
idence for causing HCM. At this time there is inconclusive
idence to support other genes causing HCM (7,9,226,227),
t research is ongoing (6,228). A single mutation in 1 of the
alleles (or copies) of a gene is sufficient to cause HCM;
wever, 5% of patients with HCM have2 mutations in the
me or different genes (23,229).
Genetic and/or clinical screening of all first-degree family
embers of patients with HCM is important to identify those
ith unrecognized disease. On the basis of family history,
inical screening, and pedigree analyses, the pattern of
heritance is ascertained to identify and counsel relatives at
sk (14). Because familial HCM is a dominant disorder, the
sk that an affected patient will transmit disease to each
fspring is 50%. When a pathogenic mutation is identified in
index patient, the genetic status of each family member
n be readily ascertained.
Because unrelated patients with HCM will have different
utations, a comprehensive sequence-based analysis of all
CM genes is necessary to define the pathogenic (e.g.,
sease causing) mutation in an index patient. Experienced
inical laboratories identify the pathogenic HCM mutation in
proximately 60% to 70% of patients with a positive family
story and approximately 10% to 50% of patients without a
mily history (6,15). Genetic testing may identify a patho-
nic mutation (e.g., analysis defines a sequence variant
own to cause HCM) or a “likely pathogenic” mutation, a
NA variant that was previously unknown as a cause of
CM but has molecular characteristics that are similar to
cognized HCM mutations. Genetic testing may also identify
ariants of uncertain significance.” Studies suggest that the
esence of 1 HCM-associated sarcomere mutation is
sociated with greater severity of disease (23,24,230,231). LVWhen genetic testing reveals a mutation in the index
tient, ascertainment of genetic status in first-degree rela-
ves can be predictive of risk for developing HCM (18).
enetic counseling should precede genetic testing of family
embers (14). Relatives with overt HCM will have the same
thogenic HCM mutation as the index patient. Pathogenic
utations may also be identified in other relatives with
known clinical status. These mutation carriers should be
aluated by physical examination, electrocardiography, and
dimensional echocardiography, and if HCM is identified,
ese individuals should undergo risk stratification (Section
13). Mutation carriers without evidence of HCM (genotype
sitive/phenotype negative) are at considerable risk for
ture development of HCM, and guidelines to evaluate these
dividuals are discussed below (188,189). Mutation-negative
mily members and their descendents have no risk for
veloping HCM and do not need further evaluation. Infor-
ation from genotyping may help define clinical manifesta-
ons and outcomes in specific families with HCM (Table 4)
–9,18,20–22,232).
.1. Cardiovascular Magnetic Resonance
MR provides superior spatial resolution with sharp contrast
tween blood and myocardium, as well as tomographic
aging of the entire LV myocardium and therefore the
portunity to more accurately characterize the presence and
stribution of LV hypertrophy in HCM.
Two-dimensional echocardiography has demonstrated the
terogeneity of the hypertrophic phenotype in patients with
CM, particularly with regard to distribution of LV hyper-
ophy and mechanisms of outflow obstruction (32,38,67,76,
0,220,234). However, there remain patients in whom the
agnosis of HCM is suspected but the echocardiogram is
conclusive, mostly because of suboptimal imaging from
or acoustic windows or when hypertrophy is localized to
ble 4. Proposed Clinical Screening Strategies With
hocardiography (and 12-Lead ECG) for Detection of
ypertrophic Cardiomyopathy With Left Ventricular Hypertrophy
Families*
e 12 y
Optional unless
Malignant family history of premature death from HCM or other
adverse complications
Patient is a competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early LV hypertrophy
e 12 to 18–21 y†
Every 12–18 mo
e 18–21 y
At onset of symptoms or at least every 5 y. More frequent intervals are
appropriate in families with a malignant clinical course or late-onset HCM
*When pathologic mutations are not identified or genetic testing is either
biguous or not performed.
†Age range takes into consideration individual variability in achieving
ysical maturity and in some patients may justify screening at an earlier age.
itial evaluation should occur no later than early pubescence (233).
ECG indicates electrocardiogram; HCM, hypertrophic cardiomyopathy; and
, left ventricular.
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ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summary December 13/20, 2011:2703–38gions of the LV myocardium not well visualized by
hocardiography (76). In 1 study, 6% of patients with
spected HCM were identified with increased LV wall
ickness (predominantly in the anterolateral wall) by CMR
t not by echocardiography (74,76,77). In addition, hyper-
ophy confined to the apex (i.e., apical HCM) may be
fficult to visualize with echocardiography but is evident
ith CMR (73,75). Furthermore, CMR can more readily
tect the presence of apical aneurysms (particularly when
all). The latter has potential implications for management
ith ICDs and/or anticoagulation. The magnitude of LV wall
ickening may be underestimated by echocardiography com-
red with CMR, particularly when this region involves the
terolateral free wall (76,77), and therefore CMR may
entify high-risk status on the basis of massive hypertrophy.
ccurate characterization of the HCM phenotype by CMR
ay also be useful in management decisions for invasive
erapies (septal myectomy or alcohol septal ablation) by
ore precisely defining the location and magnitude of hyper-
ophy, as well as characterizing the mitral and submitral
paratus and papillary muscles (235,236).
The opportunity for contrast-enhanced CMR with LGE to
entify areas of myocardial fibrosis in patients with HCM
s been the subject of a growing literature (79–81,237,238).
lthough patients with the end-stage phenotype almost uni-
rsally demonstrate such findings (49), patients with HCM
ith preserved systolic function may also have areas of LGE
9–81). Importantly, patients with HCM with evidence of
GE on CMR imaging tend to have more markers of risk of
CD, such as NSVT on Holter monitoring, than patients
ithout LGE (78,80).
It is plausible that areas of LGE (i.e., probably largely
placement myocardial fibrosis) could represent a substrate
r the generation of malignant ventricular tachyarrhythmias
HCM. Several studies have addressed this issue and have
ported either trends in such a direction or significant
sociations between the presence of LGE (not extent) and
rdiac outcome events (81,239). However, there is insuffi-
ent evidence at this time to support a significant association
tween the extent of LGE and outcome. Nonetheless, the
esent data would support a potential role of LGE as an
bitrator in decision making for primary prevention ICDs in
tients in whom risk status remains uncertain after assess-
ent of conventional risk markers (79,80).
. Concomitant Coronary Disease
hest discomfort is a common symptom in patients with
CM. A key management issue revolves around whether the
scomfort may be caused by concomitant epicardial obstruc-
ve CAD with inducible ischemia or a consequence of
icrovascular dysfunction (38). Concomitant presence of
AD in patients with HCM identifies a higher risk for
verse outcomes and potential candidates for revasculariza-
on (240,241).
Myocardial bridging of the left anterior descending coro-
ry artery is a frequent component of phenotypically ex-
essed HCM and more common than in other diseases with
without LV hypertrophy. Although it has been suggested caat ischemia secondary to bridging could be a potential
echanism for sudden death in HCM (242), there is no
nsistent evidence to support this hypothesis in either adults
children (243,244).
. Choice of Imaging Modality
.1. Invasive Coronary Arteriography
vasive coronary arteriography is indicated in patients with
CM when knowledge of these features will importantly
fluence management strategies. Coronary arteriography
ould be undertaken before alcohol septal ablation in order
define the anatomy of the septal perforators and exclude
structive coronary stenoses.
.2. Noninvasive CTA
lthough there are no published data specifically assessing
e performance characteristics of CTA for documenting the
esence or absence of epicardial CAD in HCM, there is no
ason to believe that performance of the test should differ in
tients with HCM. A high negative predictive value to
clude CAD is particularly consistent in the literature.
.3. Single Photon Emission Computed
omography Myocardial Perfusion Imaging
tress SPECT MPI in patients with HCM will often demon-
rate reversible or fixed perfusion defects consistent with
chemia or infarction, respectively, even in the absence of
icardial CAD (245,246). Several lines of evidence support
at these defects, even in the absence of symptoms, represent
ue flow abnormalities and possibly “silent” ischemia (247).
Fixed defects may also be seen with SPECT MPI, a finding
nsistent with infarction. These patients will often have the
nd-stage” clinical phenotype with reduced EF (245) and
kely correspond to patients who demonstrate LGE in CMR
udies (49).
.4. Positron Emission Tomography
ET imaging has been used in patients with HCM to study
yocardial blood flow, as well as myocardial metabolism. In
tients with HCM with normal coronary arteries, myocardial
rfusion PET studies have shown that although resting
yocardial blood flow may be similar to normal control
bjects, the augmentation of blood flow with vasodilation,
r example, dipyridamole, may be significantly blunted
48–251). However, the quantitative PET techniques used in
ese studies are not part of routine clinical practice, and the
anagement implications of identifying abnormalities in flow
serve are unresolved.
.5. Stress Echocardiography
here are no published studies addressing the performance
aracteristics of stress echocardiography to detect or exclude
AD in patients with HCM. Patients with HCM have
terogeneous wall-thickness patterns, and wall motion at
st may appear abnormal in regions of hypertrophied myo-
rdium. Therefore, stress echocardiography to detect or rule
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December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryt CAD may be unreliable in HCM but may be useful to
cument the presence or magnitude of outflow tract obstruc-
on generated by exercise (67) (Section 5.1).
. Management of HCM
reatment of patients with HCM requires a thorough under-
anding of the complex, diverse pathophysiology and natural
story and must be individualized to the patient, but the
neral approach of the writing committee is outlined in
igure 4.
.1. Asymptomatic Patients
large proportion of patients presenting with HCM are
gure 4. Treatment algorithm. ACE indicates angiotensin-convert
s; EF, ejection fraction; GL, guidelines; HCM, hypertrophic cardioymptomatic, and most will achieve a normal life expec- Hncy (213,252,253). It is essential to educate these patients
d their families about the disease process, including screen-
g of first-degree relatives and avoiding particularly strenu-
s activity or competitive athletics (88). Risk stratification
r SCD should also be performed in all patients, irrespective
whether symptoms are present (32,38).
Because concomitant CAD has a significant impact on
rvival in patients with HCM (240), it is recommended that
her risk factors that may contribute to atherosclerotic
sease be aggressively treated in concordance with existing
idelines (Figure 4) (32,86).
Hydration and avoidance of environmental situations
here vasodilatation may occur are important in the asymp-
matic patient with resting or provocable LVOT obstruction.
yme; ARB, angiotensin receptor blocker; DM, diabetes melli-
thy; HTN, hypertension; and LV, left ventricular.ing enzigh-dose diuretics and vasodilators (for treatment of other
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ese may exacerbate the degree of obstruction (3,38).
Finally, the indication for septal reduction therapy is to
prove symptoms that are not relieved by medical therapy
d that impair the patient’s quality of life, usually consistent
ith NYHA functional classes III or IV (32,38). Thus, septal
duction therapy with either septal myectomy or alcohol
ptal ablation should not be performed in the asymptomatic
tient, regardless of the severity of obstruction (32,38).
.2. Symptomatic Patients
he major goal of pharmacologic therapy in symptomatic
tients with HCM is to alleviate symptoms of exertional
spnea, palpitations, and chest discomfort, which may
flect pathophysiologic mechanisms such as LVOT obstruc-
on, reduced supply of myocardial oxygen, mitral regurgita-
on, and impaired LV diastolic relaxation and compliance
2,38,88).
Beta blockers are the mainstay of pharmacologic therapy
d the first-line agents because of their negative inotropic
fects (260) and their ability to attenuate adrenergic-induced
chycardia (Figure 4). The reduction in heart rate also
olongs the diastolic filling period, which may allow for
ore efficient inactivation of myocardial contractile proteins,
ereby improving diastolic filling (255,256).
In those patients unable to tolerate beta blockers or those
ith symptoms unresponsive to beta blockers, calcium chan-
l blockers may provide effective symptomatic relief. Vera-
mil has been the most intensively studied such agent
igure 4) (99,257). Possible mechanisms for symptomatic
provement include negative inotropic and rate-lowering
fects similar to those of beta blockers. However, the effect of
rapamil on diastolic dysfunction is controversial (258–262).
iltiazem has also been shown to improve measures of
astolic performance (263) and to prevent or diminish
yocardial ischemia (264). Both verapamil and diltiazem
ould be used cautiously in patients with severe outflow tract
struction, elevated pulmonary artery wedge pressure, and
w systemic blood pressure, because a decrease in blood
essure with treatment may trigger an increase in outflow
struction and precipitate pulmonary edema. Administration
beta-blocking drugs with either verapamil or diltiazem
ould also be used with caution because of the potential for
gh-grade atrioventricular block. Dihydropyridine class cal-
um channel blockers (e.g., nifedipine) should not be used in
tients with obstructive physiology because their vasodila-
ry effects may aggravate outflow obstruction.
In patients with obstructive HCM who remain symptom-
ic despite the use of beta blockers and calcium channel
ockers, alone or in combination, disopyramide may be
fective in ameliorating symptoms (Figure 4) (68,265).
iuretics may be effective for symptomatic relief in patients
ith pulmonary congestion but should be used judiciously in
ose with outflow tract obstruction at rest or with provocation.
.3. Invasive Therapies
or severe refractory symptoms that are attributable to LVOT
struction, invasive therapies can be used to improve quality halife (Figure 4). Surgical approaches have been used for 5
cades (52,220) so that relief of outflow tract obstruction
d symptoms can be achieved with minimal perioperative
orbidity or mortality in experienced centers (64,65). How-
er, some patients are not optimal surgical candidates (e.g.,
cause of comorbidities or advanced age) or have such a
rong desire to avoid surgery that alternative therapeutic
terventions have been implemented. Alcohol septal abla-
on, which has been used for the past 17 years, has become
e leading strategy in these circumstances (266).
.3.1. Selection of Patients
is well recognized that the appropriate selection of patients
r individual procedures is an important predictor of out-
me. Because the majority of patients with HCM can
hieve control of their symptoms with optimal pharmaco-
gic therapy, and in light of the complications inherent with
vasive therapies, a core set of clinical, anatomic, and
modynamic criteria are required before patients are con-
dered candidates for invasive therapies. Specifically, pa-
ents must have symptoms attributable to LVOT obstruction
at are refractory to optimal pharmacologic therapy. Simi-
rly, it must be demonstrated that the obstruction is caused
apposition of the mitral valve with the hypertrophied
ptum (52,220). Maximal instantaneous gradients of at least
mm Hg at rest or with physiologic provocation are
cessary to produce symptoms amenable to invasive thera-
es (32).
Given the duration of experience, documented long-term
sults, and safety data, surgical septal myectomy is consid-
ed the preferred treatment for most patients who meet these
iteria (Figure 4). Considerations that favor surgical inter-
ntion include younger age, greater septal thickness, and
ncomitant cardiac disease independently requiring surgical
rrection (e.g., intrinsic mitral valve disease or coronary
tery bypass grafting). Additionally, specific abnormalities
the mitral valve and its support apparatus can contribute
gnificantly to the generation of outflow tract obstruction,
ggesting the potential value of additional surgical ap-
oaches (e.g., plication, valvuloplasty, and papillary muscle
location) and making myectomy more appropriate than
cohol septal ablation in some patients (26,224,267–272)
mong patients who meet the core selection criteria, factors
at influence a decision to proceed with alcohol septal
lation include older or advanced age, significant comorbid-
y that selectively increases surgical risk, (e.g., significant
ncerns about lung or airway management), and the pa-
ent’s strong desire to avoid open heart surgery after a
orough discussion of both options.
.3.2. Results of Invasive Therapy for the Relief of
VOT Obstruction
ore detailed discussions specific to each type of procedure
llow in subsequent sections of this document. Overall,
ports suggest that technical success, variably defined, is
hieved in 90% to 95% of patients who undergo surgical
yectomy (273), less in septal ablation, and only in the
inority of patients studied in trials of pacemaker therapy
32,134,135,274). Patients undergoing septal ablation may
ve hemodynamic and symptomatic improvement compara-
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n be accessed by the first septal perforator and ablated.
owever, compared with septal myectomy in which the
pertrophied muscle is directly visualized and resected,
ccessful septal ablation is dependent on the variable septal
tery anatomy, which may not supply the targeted area of the
ptum in up to 20% to 25% of patients (60,275).
In a nonrandomized retrospective evaluation of patients
ith HCM 65 years of age, survival free from recurrent
mptoms favored myectomy over ablation (89% versus
%, p0.01) (60). Procedural success is associated with
ry low mortality (1% for myectomy (64,65,276), ranging
om 0% to 4% for ablation) (277–279), and low nonfatal
mplication rates (2% to 3% in experienced centers). The
ception is high-grade atrioventricular block requiring per-
anent pacemakers following septal ablation (in 10% to 20%
patients), an inherent aspect of the septal infarction
79a–c).
.3.3. Operator Experience
perator and institutional experience, including procedural
lume, is a key determinant of successful outcomes and
wer complication rates for any procedure. For HCM, a
sease of substantial heterogeneity and relatively uncommon
general cardiology practice, this is an important issue. As
consensus opinion, the writing committee recommends an
erator volume of at least 20 procedures or that the operator
ork within the context of an HCM program with a cumu-
tive procedural volume of at least 50 procedures. In addi-
on, given the data available from experienced centers,
erators and institutions should aim to achieve mortality
tes of 1% and major complication rates of 3%, with
cumented success in both hemodynamic and symptom
nefit for their patients. This is best achieved in the context
a systematic program dedicated to the multidisciplinary
d longitudinal care of patients with HCM.
.3.4. Surgical Therapy
ransaortic septal myectomy is currently considered the most
propriate treatment for the majority of patients with ob-
ructive HCM and severe symptoms unresponsive to medical
erapy (Figure 4) (126,273,280–288). Surgical results, al-
ough vastly improved in recent years, are nevertheless
mited to relatively few centers with extensive experience
d particular interest in the management of HCM (270,289).
oth the traditional myectomy (Morrow procedure) with
out a 3-cm long resection (284) or extended myectomy (a
section of about 7 cm) are currently used (270,289).
The transaortic approach remains the primary method of
posure. Virtual abolition of the LV outflow gradient and
itral regurgitation is usually accomplished by muscular
section resulting in physical enlargement of the outflow
act and by interruption of the mitral valve SAM, which is
ually responsible for the outflow gradient (297).
In selected circumstances, some surgeons have also used
ncomitant mitral valve repair, particularly when the ante-
or leaflet is elongated. Finally, enlarged or malpositioned
pillary muscles can also contribute to residual obstruction.
his can be effectively treated by shaving the hypertrophied
pillary muscles, incising papillary muscles off the ventric- lear free wall, and in selected circumstances repositioning
e papillary muscle by suture approximation to the adjacent
pillary muscle.
.3.4.1. OUTCOMES
arly Results. Based on the experience and data assembled
om multiple centers worldwide over the last 4 decades
26,273,280,282,283,285,286), septal myectomy is estab-
shed as the most effective and proven approach for reversing
e consequences of heart failure by providing amelioration
obstruction (and relief of mitral regurgitation) at rest, with
storation of functional capacity and acceptable quality of
fe at any age, exceeding that achievable with long-term
ministration of cardioactive drugs (32,290).
LV outflow gradient reduction with myectomy results from
sal septal thinning with resultant enlargement of the LVOT
ea (and redirection of forward flow with loss of the drag and
enturi effects on the mitral valve) (291) and consequently
olition of SAM and mitral-septal contact (289,292,293).
itral regurgitation is also usually eliminated without the
ed for additional mitral valve surgery (56). With myec-
my, left atrial size (and possibly long-term risk for AF) is
duced (65) and LV pressures (and wall stress) are normal-
ed (32,56,64,291,294). Thus, obstructive HCM is a surgi-
lly and mechanically reversible form of heart failure. In
perienced centers, operative risk is now particularly low, in
e range of 1% (290).
ate Results. Relief of outflow obstruction by septal my-
tomy may also extend the longevity of patients with HCM
4). Although RCTs involving myectomy surgery have not
en performed, in a nonrandomized study, myectomy re-
lted in excellent long-term survival similar to that in the
neral population. After septal myectomy, long-term actu-
ial survival was 99%, 98%, and 95% at 1, 5, and 10 years,
spectively (when considering HCM-related mortality). This
rvival rate did not differ from that expected in a matched
neral US population and was superior to that achieved by
tients with obstructed HCM who did not undergo surgical
yectomy (64). Similarly the rate of SCD or appropriate ICD
scharge after myectomy is very low (0.9%) (64,295,296).
onetheless, surgical myectomy does not eliminate the need
assess each patient’s risk for SCD and to consider
acement of an ICD in those with a significant risk burden.
.3.4.2. COMPLICATIONS
omplications following myectomy are rare when performed
experienced centers (297). The risk of complete heart block
approximately 2% with myectomy (higher in myectomy
tients with preexisting right bundle-branch block), but in
yectomy patients who have had previous alcohol septal
lation, risk is much higher (50% to 85%) (298). Iatrogenic
ntricular septal defect occurs in 1% of patients.
.3.4.3. MITRAL VALVE ABNORMALITIES AND
THER ANATOMIC ISSUES
bnormalities of the mitral valve and subvalvar apparatus
ncluding anomalous direct anterolateral papillary muscle
sertion into anterior mitral leaflet and elongated mitral
aflets) (224,299) can be identified preoperatively with TTE
or
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itral valve repair or extended myectomy techniques without
e need for mitral valve replacement.
.3.5. Alcohol Septal Ablation
irst reported in 1995 (266), alcohol septal ablation uses
anscoronary administration of absolute ethanol via a percu-
neous approach to induce a localized infarction of the basal
ptum at the point of contact of the anterior mitral valve
aflet, thereby reducing outflow tract gradient and associated
itral regurgitation and simulating the results of surgical
yectomy. Developed as an alternative to surgical septal
yectomy, the technique is particularly useful when surgery
contraindicated and in patients who are considered poor
rgical candidates (129). Since its development, alcohol
ptal ablation has been performed successfully in a large
mber of patients (62).
Contrast angiography of the septal perforator through the
lloon central lumen with simultaneous echocardiographic
idance (300,301) confirms delivery to only the target
yocardium. About 1 to 3 mL of alcohol is infused in
ntrolled fashion (59,302–304). It is important that the
lloon be inflated and that a contrast injection also show that
ere is no extravasation of dye into the distal left anterior
scending coronary artery. Contrast enhancement of other
gions (papillary muscles, free wall) indicates collateral
rculation from the septal perforator artery, and alcohol
ould not be infused. A decrease in resting and provocable
adients usually occurs immediately after the procedure
ecause of stunning), and remodeling can result in continued
variable gradient reduction over the first 3 months after the
ocedure.
.3.5.1. SELECTION OF PATIENTS
lcohol septal ablation has the potential for greater patient
tisfaction because of the absence of a surgical incision and
neral anesthesia, less overall discomfort, and a much
orter recovery time. The benefit of alcohol septal ablation
patients of advanced age is similar to that in other patients
27,305). Because the postoperative risks and complications
cardiac surgery increase with age, ablation may offer a
lective advantage in older patients, in whom operative risk
ay be increased because of comorbidities. Alcohol septal
lation is not indicated in children.
On the other hand, longer-term follow-up data are avail-
le for septal myectomy than for septal ablation, a consid-
ation relevant to the selection of patients for either septal
duction therapy. The likelihood of implantation of a per-
anent pacemaker is 4- to 5-fold higher after septal ablation
an after septal myectomy. Furthermore, patients with mas-
ve septal thickness approaching or exceeding 30 mm may
perience little or no benefit from septal ablation. The
rgeon can tailor the myectomy under direct visualization to
dress specific anatomic abnormalities of the LVOT or
itral valve apparatus, whereas alcohol septal ablation indi-
ctly (and is restricted to) targets the distribution of the septal
rforator artery.
Septal myectomy is the preferred treatment option for most
verely symptomatic patients with obstructive HCM, espe- sually in younger, healthy adults, whereas septal ablation is
eferred in patients for whom surgery is contraindicated or
nsidered high risk (particularly the elderly) (Figure 4). Data
mparing alcohol septal ablation with septal myectomy are
adequate to fully inform clinical decision making in certain
ses. For such patients, the principle of patient autonomy
ctates that it is appropriate for the informed patient to
oose between the 2 procedures.
.3.5.2. RESULTS
ecrosis of the basal ventricular septum (306) produces an
mediate fall in gradient from decreased septal contraction
90% of patients (66,279,307–309). This effect is fol-
wed by LV remodeling over 6 to 12 months, a process that
cludes scar retraction and resultant widening of the outflow
act, associated with further reduction in gradient and degree
mitral regurgitation, regression of hypertrophy, and im-
ovement in diastolic function (63,279,310–312). The ben-
cial results of alcohol septal ablation have been reported to
most 5 years after the procedure with improved functional
d angina classes, exercise capacity, and quality of life
2,279,313–316). However, hemodynamic and symptomatic
ccess is dependent on the ability to cannulate and ablate a
ptal perforator artery that supplies the area of the SAM-
ptal contact.
Although RCTs comparing surgical myectomy with alco-
l septal ablation have not been conducted and are highly
likely in the future, meta-analyses have noted similar
modynamic and functional improvement over 3 to 5 years
hen examining the cumulative average of outcomes (317–
9). What the meta-analyses do not report are a subset of
tients in whom alcohol septal ablation is unreliable because
the inability to ablate the area of the SAM-septal contact
20). Older patients, especially those considered to be at
gh surgical risk, may be well served by alcohol septal
lation, whereas younger patients may benefit most from
rgical myectomy (60,129). Despite age differences in treat-
ent allocation, with septal ablation patients on average
proximately 10 years older in clinical practice (317,318),
e 4-year survival rate is similar for the 2 procedures
0,128). Most studies that have compared surgical myec-
my and alcohol septal ablation have involved a large
ngle-center experience in which treatment assignment was
t randomized.
.3.5.3. COMPLICATIONS
approximately half of patients undergoing alcohol septal
lation, temporary complete atrioventricular block occurs
ring the procedure (321–323). Persistent complete heart
ock prompting implantation of a permanent pacemaker
curs in 10% to 20% of patients based on the available data
6). Approximately 5% of patients have sustained ventricu-
r tachyarrhythmias during hospitalization. The in-hospital
ortality rate is up to 2% (60,62,129,318). Because of the
tential for creating a ventricular septal defect, septal abla-
on should not be performed if the target septal thickness is
15 mm.
Alcohol septal ablation is a therapeutic alternative to
rgical myectomy for selected patients and produces a
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erage 10% of the overall LV wall (144,275,324). There has
en concern that the potential ventricular arrhythmogenicity
the scar created by septal ablation might augment risk in
e HCM population. Several studies have documented the
currence of sustained ventricular arrhythmias (301,314,
5–331) and SCD following septal ablation (296) in about
to 10% of patients both with or without risk factors for
CD. Patients with HCM considered to carry sufficient risk to
arrant ICD placement have an annual incidence of appro-
iate interventions for VT/ventricular fibrillation of 3% to
% (150,328,332). It is uncertain how common such events
e attributable to the procedure or alternatively to the
derlying disease, but the incidence of sustained ventricular
rhythmias after myectomy is extremely low (0.2% to 0.9%
r year) (64,295,296).
Meta-analyses have indicated no difference between septal
lation and myectomy in the medium-term incidence of
CD or all-cause mortality (317,333). Although no definitive
idence is available that the ablation scar as such increases
r does not increase) long-term risk for SCD in absolute
rms in this patient population, resolution will require
eatly extended follow-up studies in larger patient cohorts
44,325).
.3.6. DDD Pacing
plantation of a dual-chamber pacemaker was proposed as
alternative treatment for patients with severe symptomatic
structive HCM (335–337). However, there have been 3
ndomized crossover trials showing that although symptom-
ic improvement was reported by the majority of patients
llowing continuous DDD pacing, a similar frequency of
provement was reported by patients during the AAI mode
ontrol mode without pacing). These findings suggest a
acebo effect responsible for the perceived improvement in
mptoms (136,137,338). However, there is some evidence
at patients 65 years of age may be a subgroup who
hieve the greatest benefit (136). There are no data that
al-chamber pacing either reduces the risk of SCD in
tients with HCM, alters the underlying progression of
sease, or is of benefit to patients with nonobstructive HCM
36,335,339). A trial of dual-chamber pacing may be con-
dered for symptomatic patients with obstruction in whom an
D has already been implanted for high-risk status.
.3.7. LV Systolic Dysfunction
tandard heart failure therapies should be implemented in
tients with HCM when EF is 50%. Patients with HCM
ere not included in the primary prevention ICD trials for
tients with heart failure due to CAD or dilated cardiomy-
athy (and reduced EF). Prophylactic ICD implantation is
vertheless the generally accepted clinical practice for HCM
tients with systolic dysfunction.
.4. Prevention of SCD
minority of clinically recognized patients with HCM are
dged to be at increased risk for SCD, with a rate of about
per year (143–146,148,150). ICDs offer the only effectiveeans of preventing SCD and prolonging life in patients with evCM (150). Selection of patients who are appropriate for
plantation for primary as opposed to secondary prevention
n be a difficult clinical decision owing to the individuality
each patient and family, variable definitions for risk
arkers, sparse clinical data, the relative infrequency of both
CM and SCD in most clinical practices, and the cumulative
orbidity of living with an ICD.
.4.1. Established Risk Markers
.4.1.1. PRIOR PERSONAL HISTORY OF VENTRICULAR
BRILLATION, SCD, OR SUSTAINED VT
s expected, patients with HCM who have experienced SCD
sustained VT represent the highest risk for subsequent
rhythmogenic events. The annualized rate of subsequent
ents is approximately 10% per year, although it has been
own that individuals may have no recurrent events or may
ve decades-long arrhythmia-free intervals between epi-
des (145,146,148,150,340).
.4.1.2. FAMILY HISTORY OF SCD
has been recognized that SCD events can cluster in
milies. Notably, some studies have not demonstrated an
dependent link between family history of SCD and risk for
dividual patients on multivariate analysis (147,149,155),
hereas others have suggested that family history is an
dependent predictor (155). These differences may be ex-
ained in part by the relative infrequency of events but also
kely reflect variability in the definition of a family history of
CD.
.4.1.3. SYNCOPE
yncope represents a complex symptom with a multifactorial
iology that requires a careful clinical history before it can be
nsidered a potential marker for SCD (147,152). In one
alysis, syncope that was unexplained or thought to be
nsistent with arrhythmia (i.e., not neurally mediated)
owed a significant independent association with SCD only
hen the events occurred in the recent past (6 months)
52).
.4.1.4. NONSUSTAINED VENTRICULAR TACHYCARDIA
lthough sustained ventricular arrhythmia is clearly associ-
ed with SCD, the data for NSVT are less robust. However,
contemporary study showed that NSVT is independently
sociated with SCD on multivariate analysis (30) and is
ore important in younger patients (30 years of age) (33).
urthermore, exercise-induced NSVT has been found to have
dependent association with SCD (341). NSVT probably
ould not be considered in a simply binary manner (i.e., as
ther positive or negative), and there may be some value in
ng-term ambulatory monitoring when NSVT is discovered
the screening 24-hour assessment.
.4.1.5. MAXIMUM LV WALL THICKNESS
he relationship between severity of LV hypertrophy and
CD has been investigated in several studies predicated on
e concept that the more severe the disease expression, the
ore likely the individual patient is to experience adverse
ents. Most, but not all (156,342), studies have shown at
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ss and SCD (148,342,343), whereas other large studies
ve shown that when magnitude of hypertrophy is 30 mm,
ere is an independent association with SCD (147,152,158).
.4.1.6. ABNORMAL BLOOD PRESSURE RESPONSE
URING EXERCISE
or up to a third of patients with HCM, there is an inappro-
iate systemic systolic blood pressure response during exer-
se testing (defined as either a failure to increase by at least
mm Hg or a drop of at least 20 mm Hg during effort)
0,71). Two studies have shown a univariate association
tween this finding and subsequent SCD (30,71,147,149).
.4.2. Other Potential SCD Risk Modifiers
.4.2.1. LVOT OBSTRUCTION
lthough some studies have not found a significant associa-
on between LVOT obstruction and SCD (51,158,212), other
udies have found higher rates of SCD among patients with
sting gradients 30 mm Hg (30,149) and that the risk is
sitively correlated with severity of LVOT obstruction (30).
onversely, relief of outflow tract obstruction through surgi-
l myectomy is associated with very low rates of SCD
4,307). A limitation to using LVOT obstruction as an
dependent risk marker is that the obstruction in HCM is
namic and highly variable (225,344).
.4.2.2. LGE ON CMR IMAGING
here has been considerable interest in promoting LGE on
MR imaging as a potential SCD risk marker in HCM.
ecause LGE is believed to represent myocardial fibrosis or
arring, it has been hypothesized that LGE may represent
yocardium prone to ventricular tachyarrhythmia (82). In-
ed, LGE has been associated with NSVT and ventricular
topy but has not been associated with clinical SCD events
ICD discharge in published studies (78,79,82). More recent
udies have shown a relationship between LGE and SCD and
art failure, but with low positive predictive accuracy
0,81).
.4.2.3. LV APICAL ANEURYSM
subset of patients with HCM (prevalence about 2%)
velop a thin-walled LV apical aneurysm associated with
gional scarring (75) and more adverse clinical events during
llow-up, including progressive heart failure and evolution
to the end-stage phase, as well as SCD. Although data on
V aneurysms in HCM are limited, this abnormality may
arrant consideration in SCD risk-assessment strategies.
.4.2.4. GENETIC MUTATIONS
CD may cluster in certain families with HCM, and the
ssibility that specific sarcomere mutations may confer SCD
sk has been hypothesized. Indeed, several early studies of
CM pedigrees implicated certain mutations as “malignant”
0,227,345,346). However, subsequent studies of less se-
cted consecutive patients with HCM found that it was ICoblematic to infer likelihood of SCD events on the basis of
e proposed mutations, because in some instances the rate of
verse events (and prevalence of associated SCD risk
arkers) was lower in patients with “malignant” mutations
an it was in those with mutations believed to be “benign”
,347–349). The data from unselected consecutive outpa-
ents suggest that most mutations are “novel” and limited to
rticular families (“private” mutations). Therefore, routine
utational screening would appear to be of little prognostic
lue in HCM.
.4.3. Utility of SCD Risk Markers in
linical Practice
ther than cardiac arrest, each of the HCM risk factors has
w positive predictive value (approximately 10% to 20%)
d modestly high negative predictive value (85% to 95%).
ultiple risk markers in individual patients would intuitively
ggest greater risk for SCD; however, the vast majority of
tients with 1 risk marker will not experience SCD, and
mple arithmetic summing of risk markers is not precise
cause of the uncertainty implicit in assigning a relative
eight to any individual risk factor (147,156,350). Notably,
the international HCM-ICD registry (150), the number of
sk factors did not correlate with the rate of subsequent
propriate ICD discharges among presumably high-risk
tients selected for ICD placement. These data suggest that
e presence of a single risk marker may be sufficient to
arrant ICD placement in many patients, but these decisions
ed to be individualized with respect to age, the strength of
e risk factor, and the risk-benefit of lifelong ICD therapy
50,351).
.5. ICD Therapy in HCM
lthough the overall rate of SCD in HCM is approximately
per year, clearly there are individuals at higher risk for
hom prophylactic therapy may be indicated. Pharmacologic
erapy has not been demonstrated to provide protection from
CD. Conversely, the ICD has proved to be effective in
rminating life-threatening ventricular tachyarrhythmia in
CM, altering the natural course of the disease and prolong-
g life.
The decision for placement of primary prevention ICD in
CM often involves a large measure of individual clinical
dgment, particularly when the evidence for risk is ambiguous.
he potential for SCD needs to be discussed with each fully
formed HCM patient and family member in the context of
eir concerns and anxieties and should be balanced against the
sks and benefits of proposed prophylactic ICD strategy. Con-
deration of the patient’s age is warranted, particularly because
vice complications are more likely in children and young
ults over the long period of follow-up (150,351).
There have been 2 reports from an international, multicenter
gistry of patients with HCM who have undergone ICD
acement on the basis of the clinical perception of SCD
fficient to justify device therapy (150,153). Among patients
ho received a device as a result of a prior personal history of
rdiac arrest or sustained ventricular arrhythmia (secondary
evention ICD), the annualized rate of subsequent appropriate
D discharge was 10% per year. Patients with primary preven-
tio
ri
4%
no
9
It
IC
th
(3
pe
ti
up
in
vi
su
tu
pr
of
di
(f
a
ex
T
hi
le
w
a
th
T
yo
H
le
le
be
al
ha
ge
in
re
yo
ch
ha
9
R
A
in
of
th
di
E
ca
sp
fr
is
sa
be
co
it
ti
an
pl
pr
sp
pe
ab
ha
cy
ph
co
vo
sp
9
A
m
ar
bu
of
H
co
m
un
he
st
sy
bu
O
st
on
an
th
of
A
ta
H
co
R
ch
qu
an
of
fr
H
an
H
20
F
po
li
2725JACC Vol. 58, No. 25, 2011 Gersh et al.
December 13/20, 2011:2703–38 ACCF/AHA Hypertrophic Cardiomyopathy Guideline: Executive Summaryn ICDs placed on the basis of 1 or more of the conventional
sk markers experienced appropriate ICD therapy at a rate of
per year (150,153). The number of risk markers present did
t predict subsequent device discharge (150,351).
.5.1. Complications of ICD Therapy in HCM
is important to recognize and discuss with patients potential
D-related complications (both procedural and long term)
at occur at a rate of 4% per year in patients with HCM
51). Potential early problems may include pneumothorax,
ricardial effusion, pocket hematoma, acute pocket infec-
on, and/or lead dislodgment. Late complications include
per extremity deep venous thrombosis, lead dislodgment,
fection, high defibrillation threshold necessitating lead re-
sion, and inappropriate shocks, that is, shocks triggered by
praventricular arrhythmias, sinus tachycardia, lead frac-
res or dislodgment, oversensing, double counting, and
ogramming malfunctions.
Reported rates of complications include approximately 25%
patients with HCM who experienced inappropriate ICD
scharge; 6% to 13% who experienced lead complications
racture, dislodgment, oversensing); 4% to 5% who developed
device-related infection; and approximately 2% to 3% who
perienced bleeding or thrombosis complications (150,351).
he rate of inappropriate shocks and lead fractures appears to be
gher in children than in adults, largely because their activity
vel and body growth places continual strain on the leads,
hich are the weakest link in the system (143). ICD leads fail at
rate of 0.5% to 1% per year, although there are data showing
at failure rates are increased in younger populations (160).
his issue is of particular concern, given the long periods that
ung patients will have prophylactically implanted devices.
Industry-related ICD problems have affected patients with
CM. Prominent recalls have included defective generators
ading to several deaths (352) and small-diameter high-voltage
ads prone to fracture (160,353). The implant procedure has
en largely free of significant risk, without reported deaths,
though selected patients with extreme hypertrophy or who
ve received amiodarone may require high-energy output
nerators or epicardial lead systems (354).
In patients with LVOT obstruction in whom ICDs are
dicated, dual-chamber pacing may have the potential to
duce gradient and symptoms (Section 2.10). In general, the
unger the patient, the more appropriate it is for single-
amber devices to be used to decrease the amount of
rdware in the venous system.
.6. Participation in Competitive or
ecreational Sports and Physical Activity
number of large cohort studies from the United States
dicate that HCM is the most common cardiovascular cause
SCD in young athletes, accounting for about one third of
ese events (166–168,355). The American College of Car-
ology Bethesda Conference No. 36 (163,339), as well as the
uropean Society of Cardiology guidelines (164,356) indi-
te that risk for SCD is increased during intense competitive
orts and also suggest that the removal of these individuals
om the athletic arena can diminish their risk. This principle
the basis for disqualification of athletes with HCM from fonctioned high school and college sports (163,356). It should
underscored that these consensus recommendations for
mpetitive athletes are independent of those for noncompet-
ive, informal recreational sporting activities (87).
General recommendations for recreational exercise in pa-
ents with HCM should be tailored to the individual’s desires
d abilities; however, certain guidelines prevail. For exam-
e, aerobic exercise as opposed to isometric exercise is
eferable. Patients with HCM should avoid recreational
orts in which participation is intense and simulates com-
titive organized athletics. Also, burst exertion, in which an
rupt increase in heart rate is triggered (e.g., sprinting in
lf-court basketball), is less desirable than swimming laps or
cling. Finally, it is prudent for such patients to avoid
ysical activity in extreme environmental conditions of heat,
ld, or high humidity, with attention paid to maintaining
lume status. Detailed recommendations for individual
orts appear in Table 2.
.7. Atrial Fibrillation
F is an important cause of symptoms, morbidity, and even
ortality in patients with HCM (50,172). Patients with HCM
e at increased risk of AF compared with age-matched cohorts,
t AF is seldom seen in patients with HCM who are30 years
age and becomes more prevalent with age. AF occurring in
CM may not be associated with symptoms or hemodynamic
mpromise in one third of patients but is poorly tolerated in
any others. There is evidence that AF is an indicator of
favorable prognosis, including increased risk of HCM-related
art failure, death, and stroke (172,357).
Therapy for AF includes prevention of thromboembolic
roke and controlling symptoms (Figure 5). The risk of
stemic embolization is high in patients with HCM with AF
t is not related to the severity of symptoms (50,172).
ccurrence of paroxysmal, persistent, or chronic AF is a
rong indication for anticoagulation with a vitamin K antag-
ist (170). Whether there is a threshold for AF that warrants
ticoagulation is unresolved; however, given the high risk of
romboembolism in HCM, even patients with short episodes
AF should be strongly considered for anticoagulation.
spirin should be reserved for those who cannot or will not
ke warfarin or other oral anticoagulants, but its efficacy in
CM is unestablished.
Symptom control may be attained with adequate rate
ntrol, although many patients will require rhythm control.
ate control is best maintained by beta blockers and calcium
annel blockers. High doses of these agents may be re-
ired. Digoxin may modestly reduce ventricular rate at rest
d to a lesser extent with exertion. Because there is a paucity
data on rhythm control in patients with HCM, evidence
om other patient populations is extrapolated to HCM.
owever, whether patients with HCM respond similarly to
tiarrhythmic agents is not clear. The “2011 ACCF/AHA/
RS Focused Updates Incorporated Into the ACC/AHA/ESC
06 Guidelines for the Management of Patients With Atrial
ibrillation” state that disopyramide and amiodarone are
tential agents for rhythm control (170). The limited pub-
shed data on amiodarone suggest that it is safe and effective
r patients with HCM (358–361). Disopyramide has been
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struction, but its safety and efficacy in AF are not well
tablished (68,362). Dronedarone, an antiarrhythmic agent
milar to amiodarone but lacking the iodine moiety and
uch of the long-term toxicity, has been approved for use in
e United States. There are no data regarding the efficacy of
onedarone or the use of flecainide and propafenone in
tients with HCM. The management of atrial flutter in HCM
similar to that in other disease states, including the role of
diofrequency ablation.
The long-term benefits of radiofrequency ablation versus
tiarrhythmic drugs in patients with HCM remain to be
tablished. It does appear that early success and complica-
on rates are similar between HCM and other forms of heart
sease or absence of heart disease (175,178,179,363). The
rgical maze procedure for AF has shown some limited
ccess (364); however, whether a prophylactic or therapeutic
rgical maze procedure is indicated for patients undergoing
her open chest surgical procedures (i.e., septal myectomy)
unresolved.
0. Occupational Considerations
2002, the U.S. Department of Transportation Federal
gure 5. Management of AF in HCM. AF indicates atrial fibrillation
anent pacemaker; and PVI, pulmonary vein isolation.otor Carrier Safety Administration published its “Car-ovascular Advisory Panel Guidelines for the Medical
xamination of Commercial Motor Vehicle Drivers.” The
idelines state that “irrespective of symptoms, a person
ould not be certified as a [commercial motor vehicle]
iver if a firm diagnosis of [HCM] is made . . . .” (365,
83). Although consideration has subsequently been
ven to liberalizing this restriction, the guidelines have
t yet been revised.
The criteria for the disqualification of aircraft pilots with
rdiovascular disease are set by the Federal Aviation Ad-
inistration. Currently, HCM is regarded as generally incom-
tible with the highest grade aviation license for commercial
lots, based on the unpredictable risk for impairment in the
ckpit attributable to HCM (367).
he Federal Motor Carrier Safety Administration defines commercial motor
hicle as a motor vehicle or combination of motor vehicles used in commerce to
nsport passengers or property if the motor vehicle:
(a) has a gross combination weight rating of 11,794 kg (26,001 lb) inclusive of
a towed unit(s) with a gross vehicle weight rating of 4,536 kg (10,000 lb); or
(b) has a gross vehicle weight rating of 11,794 kg (26,001 lb); or
(c) is designed to transport 16 passengers, including the driver; or
(d) is of any size and is used in the transportation of hazardous materials as
atrioventricular; INR, international normalized ratio; PPM, per-; AV,defined [by the Federal Motor Carrier Safety Administration] (366).
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